<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td></td><td></td></tr>
<tr><td>Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call February 10, 2026 5:00 PM EST<br><br>Company Participants<br><br>Bernard Zovighian - CEO & Director<br>Scott Ullem - Corporate VP & CFO<br>Daniel Lippis - Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific)<br>Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies<br><br>Conference Call Participants<br><br>Robert Marcus - JPMorgan Chase & Co, Research Division<br>Travis Steed - BofA Securities, Research Division<br>Larry Biegelsen - Wells Fargo Securities, LLC, Research Division<br>David Roman - Goldman Sachs Group, Inc., Research Division<br>Joanne Wuensch - Citigroup Inc., Research Division<br>Matthew Taylor - Jefferies LLC, Research Division<br>Vijay Kumar - Evercore ISI Institutional Equities, Research Division<br><br>Presentation<br><br>Operator<br><br>Greetings, and welcome to Edwards Lifesciences' Fourth Quarter 2025 Results Conference Call.[Operator Instructions]<br><br>Please note that this conference is being recorded.</td><td>ì—ë“œì›Œì¦ˆ ë¼ì´í”„ì‚¬ì´ì–¸ì‹œìŠ¤(Edwards Lifesciences Corporation, EW) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 2ì›” 10ì¼ ì˜¤í›„ 5ì‹œ(ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>ë²„ë‚˜ë“œ ì¡°ë¹„ê¸°ì•ˆ(Bernard Zovighian) - ìµœê³ ê²½ì˜ì(CEO) ê²¸ ì´ì‚¬<br>ìŠ¤ì½§ ìš¸ë ˜(Scott Ullem) - ê¸°ì—… ë¶€ì‚¬ì¥ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)<br>ëŒ€ë‹ˆì–¼ ë¦¬í”¼ìŠ¤(Daniel Lippis) - JAPAC(ì¼ë³¸, ëŒ€ì¤‘í™”ê¶Œ ë° ì•„ì‹œì•„íƒœí‰ì–‘) ê¸°ì—… ë¶€ì‚¬ì¥<br>ë‹¤ë¹ˆ ì´ˆí”„ë¼(Daveen Chopra) - ê²½ì¹´í…Œí„° ìŠ¹ëª¨íŒë§‰ ë° ì‚¼ì²¨íŒë§‰ ì¹˜ë£Œ ê¸°ì—… ë¶€ì‚¬ì¥<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ê°€ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>ë¡œë²„íŠ¸ ë§ˆì»¤ìŠ¤(Robert Marcus) - JPëª¨ê±´ ì²´ì´ìŠ¤(JPMorgan Chase & Co), ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>íŠ¸ë˜ë¹„ìŠ¤ ìŠ¤í‹°ë“œ(Travis Steed) - ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ì¦ê¶Œ(BofA Securities), ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë˜ë¦¬ ë¹„ê²”ì„¼(Larry Biegelsen) - ì›°ìŠ¤íŒŒê³  ì¦ê¶Œ(Wells Fargo Securities, LLC), ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë°ì´ë¹„ë“œ ë¡œë§Œ(David Roman) - ê³¨ë“œë§Œì‚­ìŠ¤ ê·¸ë£¹(Goldman Sachs Group, Inc.), ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì¡°ì•¤ ìš°ì—”ì‰¬(Joanne Wuensch) - ì‹œí‹°ê·¸ë£¹(Citigroup Inc.), ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§¤íŠœ í…Œì¼ëŸ¬(Matthew Taylor) - ì œí”„ë¦¬ìŠ¤(Jefferies LLC), ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¹„ì œì´ ì¿ ë§ˆë¥´(Vijay Kumar) - ì—ë²„ì½”ì–´ ISI(Evercore ISI) ê¸°ê´€íˆ¬ìê°€ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ì—ë“œì›Œì¦ˆ ë¼ì´í”„ì‚¬ì´ì–¸ì‹œìŠ¤ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­]<br><br>ë³¸ ì»¨í¼ëŸ°ìŠ¤ëŠ” ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>I will now turn the conference over to your host, Gerianne Sarte. Thank you. You may begin. Unknown Executive<br><br>Thank you. Good afternoon, and thank you for joining us. This is Gerianne Sarte, I'm the incoming Senior Vice President of Investor Relations. With me on today's call is our CEO, Bernard Zovighian; and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Dan Lippis, our global leader of TAVR; and Daveen Chopra, who has global responsibility for TMTT, Surgical and IHFM. Just after the close of regular trading, Edwards Lifesciences released fourth quarter and full year 2025 financial results.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ í˜¸ìŠ¤íŠ¸ì´ì‹  Gerianne Sarteë‹˜ê»˜ íšŒì˜ë¥¼ ë„˜ê²¨ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. ì‹œì‘í•˜ì…”ë„ ë©ë‹ˆë‹¤.<br><br>ë¯¸ìƒì˜ ì„ì›<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì €ëŠ” ì°¨ê¸° íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥ Gerianne Sarteì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ëŠ” ì €í¬ CEO Bernard Zovighianê³¼ CFO Scott Ullemì´ í•¨ê»˜ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì—ëŠ” TAVR ê¸€ë¡œë²Œ ì±…ì„ì Dan Lippisì™€ TMTT, Surgical ë° IHFM ê¸€ë¡œë²Œ ì±…ì„ì Daveen Chopraê°€ í•¨ê»˜ í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì •ê·œ ê±°ë˜ ì¢…ë£Œ ì§í›„, Edwards LifesciencesëŠ” 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì¬ë¬´ ì‹¤ì ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>During today's call, management will discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today. Additionally, these statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements.</td><td>ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ê²½ì˜ì§„ì€ ë³´ë„ìë£Œ ë° ì²¨ë¶€ëœ ì¬ë¬´ì œí‘œì— í¬í•¨ëœ ì‹¤ì ì„ ë…¼ì˜í•œ í›„, ë‚¨ì€ ì‹œê°„ì€ ì§ˆì˜ì‘ë‹µì— í• ì• í•  ì˜ˆì •ì…ë‹ˆë‹¤. ê²½ì˜ì§„ì´ ì¶”ì •ì¹˜, ê°€ì • ë° ì „ë§ì— ê¸°ë°˜í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì„ í•  ê²ƒì„ì„ ìœ ì˜í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ëŸ¬í•œ ì§„ìˆ ì€ ì§„ìˆ ì´ ì´ë£¨ì–´ì§„ ë‚ ì§œë¥¼ ê¸°ì¤€ìœ¼ë¡œë§Œ ìœ íš¨í•˜ë©°, EdwardsëŠ” ì˜¤ëŠ˜ ì´í›„ ì´ë¥¼ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ë¥¼ ì§€ì§€ ì•ŠìŠµë‹ˆë‹¤. ë˜í•œ, ì´ëŸ¬í•œ ì§„ìˆ ì—ëŠ” ì‹¤ì œ ê²°ê³¼ê°€ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— ëª…ì‹œë˜ê±°ë‚˜ ì•”ì‹œëœ ë‚´ìš©ê³¼ ì¤‘ëŒ€í•˜ê²Œ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆëŠ” ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Factors that could cause these differences can be found in today's press release and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to constant currency sales growth which is defined in the financial results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release. Quarterly and full year growth rates refer to continuing operation. With that, I'll turn the call over to Bernard for his comments. Bernard Zovighian<br>CEO & Director<br><br>Thank you, Gerianne, and welcome, everyone.</td><td>ì˜¤ëŠ˜ ë°œí‘œëœ ë³´ë„ìë£Œì™€ Edwardsì˜ ê¸°íƒ€ SEC ì œì¶œ ì„œë¥˜ì—ì„œ ì´ëŸ¬í•œ ì°¨ì´ë¥¼ ì•¼ê¸°í•  ìˆ˜ ìˆëŠ” ìš”ì¸ë“¤ì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìœ¼ë©°, ëª¨ë‘ íšŒì‚¬ ì›¹ì‚¬ì´íŠ¸ edwards.comì—ì„œ ì—´ëŒ ê°€ëŠ¥í•©ë‹ˆë‹¤. ë³„ë„ë¡œ ì–¸ê¸‰í•˜ì§€ ì•ŠëŠ” í•œ, ë§¤ì¶œ ì„±ì¥ì— ëŒ€í•œ ì €í¬ ë…¼í‰ì€ ì˜¤ëŠ˜ ì´ˆ ë°œí‘œëœ ì¬ë¬´ ì‹¤ì  ë³´ë„ìë£Œì— ì •ì˜ëœ ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ ë§¤ì¶œ ì„±ì¥ë¥ ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ì–¸ê¸‰ëœ GAAP ê¸°ì¤€ê³¼ ë¹„GAAP ê¸°ì¤€ ìˆ˜ì¹˜ ê°„ì˜ ì¡°ì • ë‚´ì—­ë„ ì˜¤ëŠ˜ ë³´ë„ìë£Œì— í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë¶„ê¸°ë³„ ë° ì—°ê°„ ì„±ì¥ë¥ ì€ ê³„ì†ì˜ì—…ë¶€ë¬¸ì„ ê¸°ì¤€ìœ¼ë¡œ í•©ë‹ˆë‹¤. ê·¸ëŸ¼ Bernardì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Bernard Zovighian<br>CEO ê²¸ ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Gerianne. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ëª¨ë‘ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I am pleased to introduce Gerianne Sarte as our new Head of Investor Relations at Edwards. Gerianne has an extensive background in med tech and as a leader in our global finance organization prior to moving to this new position. You'll be seeing and hearing from her going forward and I know she looks forward to getting to know you. Now let me turn to discussing Q4 and 2025 results. We delivered a strong quarter, growing at 11.6% and a strong full year 2025, growing at 10.7%.</td><td>ì—ë“œì›Œì¦ˆì˜ ìƒˆë¡œìš´ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ì±…ì„ìë¡œ Gerianne Sarteë¥¼ ì†Œê°œí•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. Gerianneì€ ë©”ë“œí…Œí¬ ë¶„ì•¼ì—ì„œ í’ë¶€í•œ ê²½ë ¥ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ë²ˆ ìƒˆë¡œìš´ ì§ì±…ìœ¼ë¡œ ì´ë™í•˜ê¸° ì „ì—ëŠ” ê¸€ë¡œë²Œ ì¬ë¬´ ì¡°ì§ì˜ ë¦¬ë”ë¡œ í™œë™í–ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ì—¬ëŸ¬ë¶„ê»˜ì„œ ê·¸ë…€ë¥¼ ë³´ê³  ë“£ê²Œ ë˜ì‹¤ ê²ƒì´ë©°, ê·¸ë…€ë„ ì—¬ëŸ¬ë¶„ê³¼ ì•Œê²Œ ë˜ê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ 4ë¶„ê¸°ì™€ 2025ë…„ ì‹¤ì ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 11.6% ì„±ì¥í•˜ë©° ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ë‹¬ì„±í–ˆê³ , 10.7% ì„±ì¥í•˜ë©° ê°•ë ¥í•œ 2025ë…„ í•œ í•´ë¥¼ ë³´ëƒˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is the result of our differentiated strategy with a clear vision around three key elements: focusing thoroughly on structural heart, solving large, urgent and very complex patient needs and pursuing unique opportunities to innovate and lead. This is only possible due to our deeply experienced teams, their excellent execution and their commitment to patients worldwide. With our achievement in 2025, we are entering 2026 with strength and momentum globally with many growth catalysts in each area across the company.</td><td>ì´ëŠ” ì„¸ ê°€ì§€ í•µì‹¬ ìš”ì†Œë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ ëª…í™•í•œ ë¹„ì „ì„ ê°€ì§„ ì°¨ë³„í™”ëœ ì „ëµì˜ ê²°ê³¼ì…ë‹ˆë‹¤: êµ¬ì¡°ì  ì‹¬ì¥ì§ˆí™˜ì— ì² ì €íˆ ì§‘ì¤‘í•˜ê³ , ëŒ€ê·œëª¨ì˜ ì‹œê¸‰í•˜ê³  ë§¤ìš° ë³µì¡í•œ í™˜ì ë‹ˆì¦ˆë¥¼ í•´ê²°í•˜ë©°, í˜ì‹ ì„ ì£¼ë„í•  ìˆ˜ ìˆëŠ” ë…íŠ¹í•œ ê¸°íšŒë¥¼ ì¶”êµ¬í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì˜¤ì§ ìš°ë¦¬ì˜ í’ë¶€í•œ ê²½í—˜ì„ ë³´ìœ í•œ íŒ€ë“¤, ê·¸ë“¤ì˜ íƒì›”í•œ ì‹¤í–‰ë ¥, ê·¸ë¦¬ê³  ì „ ì„¸ê³„ í™˜ìë“¤ì— ëŒ€í•œ í—Œì‹  ë•ë¶„ì— ê°€ëŠ¥í•©ë‹ˆë‹¤. 2025ë…„ì˜ ì„±ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì „ì‚¬ì ìœ¼ë¡œ ê° ì˜ì—­ì—ì„œ ë§ì€ ì„±ì¥ ì´‰ë§¤ë¥¼ ê°€ì§€ê³  ì „ ì„¸ê³„ì ìœ¼ë¡œ ê°•ë ¥í•œ í˜ê³¼ ëª¨ë©˜í…€ì„ ê°€ì§€ê³  2026ë…„ì„ ë§ì´í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Starting with TAVR, there is a renewed focus on SAPIEN across the healthcare ecosystem, led by the 7-year PARTNER III and the 10-year PARTNER II data which confirm the long-term durability and proven valve performance of the SAPIEN platform. This data presented last October at TCT reinforced the confidence physicians and patients have in Edwards TAVR and set a new clinical benchmark for safety, efficacy, durability and lifetime management of patients. In addition, the practice-changing EARLY TAVR trial is resonating with the clinical community, starting with the guideline changes in Europe.</td><td>TAVRë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì˜ë£Œ ìƒíƒœê³„ ì „ë°˜ì—ì„œ SAPIENì— ëŒ€í•œ ê´€ì‹¬ì´ ìƒˆë¡­ê²Œ ì§‘ì¤‘ë˜ê³  ìˆìœ¼ë©°, ì´ëŠ” 7ë…„ê°„ì˜ PARTNER III ì—°êµ¬ì™€ 10ë…„ê°„ì˜ PARTNER II ë°ì´í„°ê°€ ì£¼ë„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë°ì´í„°ë“¤ì€ SAPIEN í”Œë«í¼ì˜ ì¥ê¸° ë‚´êµ¬ì„±ê³¼ ê²€ì¦ëœ íŒë§‰ ì„±ëŠ¥ì„ í™•ì¸ì‹œì¼œ ì£¼ì—ˆìŠµë‹ˆë‹¤. ì§€ë‚œ 10ì›” TCTì—ì„œ ë°œí‘œëœ ì´ ë°ì´í„°ëŠ” ì˜ì‚¬ì™€ í™˜ìë“¤ì´ Edwards TAVRì— ëŒ€í•´ ê°–ê³  ìˆëŠ” ì‹ ë¢°ë¥¼ ê°•í™”í–ˆìœ¼ë©°, í™˜ìì˜ ì•ˆì „ì„±, ìœ íš¨ì„±, ë‚´êµ¬ì„± ë° í‰ìƒ ê´€ë¦¬ì— ëŒ€í•œ ìƒˆë¡œìš´ ì„ìƒ ê¸°ì¤€ì„ ìˆ˜ë¦½í–ˆìŠµë‹ˆë‹¤. ë˜í•œ, ì§„ë£Œ ê´€í–‰ì„ ë³€í™”ì‹œí‚¤ëŠ” EARLY TAVR ì„ìƒì‹œí—˜ì€ ìœ ëŸ½ì˜ ê°€ì´ë“œë¼ì¸ ë³€ê²½ì„ ì‹œì‘ìœ¼ë¡œ ì„ìƒ ì»¤ë®¤ë‹ˆí‹°ì—ì„œ í° ë°˜í–¥ì„ ì¼ìœ¼í‚¤ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Together, all of these will have a lasting impact on the continued expansion of a SAPIEN platform globally. Continuing with TMTT, growth is fueled by a comprehensive portfolio of repair and replacement therapies and strengthened by new options for patients. These include the launch of SAPIEN M3, the scaling of EVOQUE, the upcoming introduction of next gen PASCAL in Q4 of this year and the introduction of PASCAL for U.S. tricuspid patients also in Q4. Together, these are significant advancements for mitral and tricuspid patients and represent large opportunities to achieve our $2 billion revenue expectation for TMTT in 2030.</td><td>ì´ ëª¨ë“  ê²ƒë“¤ì´ ì „ ì„¸ê³„ì ìœ¼ë¡œ SAPIEN í”Œë«í¼ì˜ ì§€ì†ì ì¸ í™•ì¥ì— ì§€ì†ì ì¸ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì…ë‹ˆë‹¤. TMTTë¡œ ì´ì–´ê°€ë©´, ì„±ì¥ì€ í¬ê´„ì ì¸ ìˆ˜ë³µ ë° ì¹˜í™˜ ì¹˜ë£Œë²• í¬íŠ¸í´ë¦¬ì˜¤ì— ì˜í•´ ì´‰ì§„ë˜ê³  í™˜ìë“¤ì„ ìœ„í•œ ìƒˆë¡œìš´ ì˜µì…˜ë“¤ë¡œ ê°•í™”ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” SAPIEN M3ì˜ ì¶œì‹œ, EVOQUEì˜ í™•ëŒ€, ì˜¬í•´ 4ë¶„ê¸° ì°¨ì„¸ëŒ€ PASCALì˜ ì¶œì‹œ ì˜ˆì •, ê·¸ë¦¬ê³  ì—­ì‹œ 4ë¶„ê¸°ì— ë¯¸êµ­ ì‚¼ì²¨íŒë§‰ í™˜ìë“¤ì„ ìœ„í•œ PASCALì˜ ë„ì…ì´ í¬í•¨ë©ë‹ˆë‹¤. ì´ë“¤ì€ ëª¨ë‘ ìŠ¹ëª¨íŒë§‰ ë° ì‚¼ì²¨íŒë§‰ í™˜ìë“¤ì„ ìœ„í•œ ì¤‘ìš”í•œ ì§„ì „ì´ë©°, 2030ë…„ê¹Œì§€ TMTT ë¶€ë¬¸ì—ì„œ 20ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ ëª©í‘œë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” í° ê¸°íšŒë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>Overall for Edwards in 2026, we have increased confidence in meeting our 8% to 10% sales growth guidance as well as in our EPS guidance. We are looking forward to an updated national coverage determination for TAVR, which may present a potential tailwind later this year, recognizing that our impressive results in 2025 have set a higher bar for 2026, especially in the second half. Long term, we are well positioned to execute our compelling growth strategy. And specifically over the next 3 years, we will be pioneering new therapies, launching next generation of existing technologies as well as expanding indication to impact more patients.</td><td>2026ë…„ ì—ë“œì›Œì¦ˆ ì „ì²´ì ìœ¼ë¡œëŠ” 8%~10% ë§¤ì¶œ ì„±ì¥ ê°€ì´ë˜ìŠ¤ì™€ ì£¼ë‹¹ìˆœì´ìµ(EPS) ê°€ì´ë˜ìŠ¤ ë‹¬ì„±ì— ëŒ€í•œ í™•ì‹ ì´ ë†’ì•„ì¡ŒìŠµë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ì— ì ì¬ì  ìˆœí’ì´ ë  ìˆ˜ ìˆëŠ” TAVRì— ëŒ€í•œ ì „êµ­ ë³´í—˜ê¸‰ì—¬ ê²°ì •(NCD) ì—…ë°ì´íŠ¸ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, 2025ë…„ì˜ ì¸ìƒì ì¸ ì‹¤ì ì´ 2026ë…„, íŠ¹íˆ í•˜ë°˜ê¸°ì— ë” ë†’ì€ ê¸°ì¤€ì„ ì„¤ì •í–ˆë‹¤ëŠ” ì ì„ ì¸ì‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¥ê¸°ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” ì„¤ë“ë ¥ ìˆëŠ” ì„±ì¥ ì „ëµì„ ì‹¤í–‰í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. êµ¬ì²´ì ìœ¼ë¡œ í–¥í›„ 3ë…„ê°„ ì‹ ê·œ ì¹˜ë£Œë²•ì„ ê°œì²™í•˜ê³ , ì°¨ì„¸ëŒ€ ê¸°ì¡´ ê¸°ìˆ ì„ ì¶œì‹œí•˜ë©°, ë” ë§ì€ í™˜ìë“¤ì—ê²Œ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆë„ë¡ ì ì‘ì¦ì„ í™•ëŒ€í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our talented team of 16,000 employees create, develop and enable treatment of patients globally. With a highly differentiated and complete portfolio of therapy to address aortic, pulmonic, mitral and tricuspid valve diseases. We take very seriously responsibility of investing in the development of safe and effective value therapies with proven long-term durability. Valve technology requires dedicated focus and generation of world-class clinical evidence that will continue to differentiate Edwards. I am confident that our technology will remain the first choice of clinicians to transform the care of their patients.</td><td>ì „ ì„¸ê³„ì ìœ¼ë¡œ 16,000ëª…ì˜ ìš°ìˆ˜í•œ ì„ì§ì›ë“¤ì´ í™˜ì ì¹˜ë£Œë¥¼ ê°œë°œí•˜ê³  ê°€ëŠ¥í•˜ê²Œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ëŒ€ë™ë§¥íŒ, íë™ë§¥íŒ, ìŠ¹ëª¨íŒ ë° ì‚¼ì²¨íŒ ì§ˆí™˜ì„ ë‹¤ë£¨ëŠ” ê³ ë„ë¡œ ì°¨ë³„í™”ë˜ê³  ì™„ì „í•œ ì¹˜ë£Œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì…ì¦ëœ ì¥ê¸° ë‚´êµ¬ì„±ì„ ê°–ì¶˜ ì•ˆì „í•˜ê³  íš¨ê³¼ì ì¸ íŒë§‰ ì¹˜ë£Œë²• ê°œë°œì— íˆ¬ìí•˜ëŠ” ì±…ì„ì„ ë§¤ìš° ì¤‘ìš”í•˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. íŒë§‰ ê¸°ìˆ ì€ ì „ë¬¸ì ì¸ ì§‘ì¤‘ê³¼ ì„¸ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì„ìƒ ê·¼ê±° ìƒì„±ì„ í•„ìš”ë¡œ í•˜ë©°, ì´ëŠ” ì•ìœ¼ë¡œë„ ì—ë“œì›Œì¦ˆë¥¼ ì°¨ë³„í™”í•  ê²ƒì…ë‹ˆë‹¤. ì €ëŠ” ìš°ë¦¬ì˜ ê¸°ìˆ ì´ í™˜ì ì¹˜ë£Œë¥¼ í˜ì‹ í•˜ê³ ì í•˜ëŠ” ì„ìƒì˜ë“¤ì˜ ì²« ë²ˆì§¸ ì„ íƒìœ¼ë¡œ ë‚¨ì„ ê²ƒì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Leveraging our experience, we are extending into structural heart failure and aortic regurgitation or AR for the many patients who are not well served today. This will create additional growth opportunities and extend our structural heart leadership. In 2027 and beyond, we continue to expect average annual sales growth of 10% with constant currency operating margin expansion as we continue to address patients in need by advancing novel therapies to extend lives, improve quality of life and provide greater impact and efficiency for health systems. Now I will provide an overview of Q4 sales performance by product group.</td><td>ìš°ë¦¬ì˜ ê²½í—˜ì„ í™œìš©í•˜ì—¬, í˜„ì¬ ì ì ˆí•œ ì¹˜ë£Œë¥¼ ë°›ì§€ ëª»í•˜ê³  ìˆëŠ” ë§ì€ í™˜ìë“¤ì„ ìœ„í•´ êµ¬ì¡°ì  ì‹¬ë¶€ì „ê³¼ ëŒ€ë™ë§¥íŒë§‰ ì—­ë¥˜ì¦(AR) ë¶„ì•¼ë¡œ ì‚¬ì—…ì„ í™•ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¶”ê°€ì ì¸ ì„±ì¥ ê¸°íšŒë¥¼ ì°½ì¶œí•˜ê³  êµ¬ì¡°ì  ì‹¬ì¥ì§ˆí™˜ ë¶„ì•¼ì—ì„œì˜ ë¦¬ë”ì‹­ì„ í™•ëŒ€í•  ê²ƒì…ë‹ˆë‹¤. 2027ë…„ ì´í›„ì—ë„ ìš°ë¦¬ëŠ” í™˜ìë“¤ì˜ ìƒëª…ì„ ì—°ì¥í•˜ê³ , ì‚¶ì˜ ì§ˆì„ ê°œì„ í•˜ë©°, ì˜ë£Œ ì‹œìŠ¤í…œì— ë” í° ì˜í–¥ë ¥ê³¼ íš¨ìœ¨ì„±ì„ ì œê³µí•˜ëŠ” í˜ì‹ ì ì¸ ì¹˜ë£Œë²•ì„ ë°œì „ì‹œí‚´ìœ¼ë¡œì¨ í™˜ìë“¤ì˜ ìš”êµ¬ë¥¼ ì§€ì†ì ìœ¼ë¡œ í•´ê²°í•´ ë‚˜ê°€ë©´ì„œ, ì—°í‰ê·  ë§¤ì¶œ ì„±ì¥ë¥  10%ì™€ ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ ì˜ì—…ì´ìµë¥  í™•ëŒ€ë¥¼ ì§€ì†ì ìœ¼ë¡œ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ì œí’ˆêµ°ë³„ 4ë¶„ê¸° ë§¤ì¶œ ì‹¤ì ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>TAVR overall procedural growth in the quarter remained in the high single digit. And for Edwards, TAVR's fourth quarter global sales of $1.16 billion increased 10.6% over the prior year and slightly sequentially over a high Q3, which was inconsistent with typical summer seasonality. The Q4 performance reflected clinicians elevated focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis. Edwards TAVR procedural growth was comparable across the U.S. and OUS. And our average price and competitive position were stable on a global basis.</td><td>TAVR ì „ì²´ ì‹œìˆ  ì„±ì¥ë¥ ì€ ì´ë²ˆ ë¶„ê¸°ì— í•œ ìë¦¿ìˆ˜ í›„ë°˜ëŒ€ë¥¼ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ì—ë“œì›Œì¦ˆì˜ ê²½ìš°, TAVR 4ë¶„ê¸° ê¸€ë¡œë²Œ ë§¤ì¶œì€ 11ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 10.6% ì¦ê°€í–ˆìœ¼ë©°, ë†’ì€ ì‹¤ì ì„ ê¸°ë¡í–ˆë˜ 3ë¶„ê¸° ëŒ€ë¹„í•´ì„œë„ ì†Œí­ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¼ë°˜ì ì¸ ì—¬ë¦„ì²  ê³„ì ˆì„±ê³¼ëŠ” ë‹¤ë¥¸ ì–‘ìƒì´ì—ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì‹¤ì ì€ ì„ìƒì˜ë“¤ì´ SAPIEN ì¹˜ë£Œë²•ì— ëŒ€í•œ ê´€ì‹¬ì„ ë†’ì´ê³  ì¤‘ì¦ ëŒ€ë™ë§¥ í˜‘ì°©ì¦ì„ ì•“ê³  ìˆëŠ” í™˜ìë“¤ì— ëŒ€í•œ ì„ ì œì  ì§ˆí™˜ ê´€ë¦¬ì— ì§‘ì¤‘í•œ ê²°ê³¼ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì—ë“œì›Œì¦ˆì˜ TAVR ì‹œìˆ  ì„±ì¥ë¥ ì€ ë¯¸êµ­ê³¼ í•´ì™¸ ì‹œì¥ì—ì„œ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í‰ê·  ê°€ê²©ê³¼ ê²½ìŸì  ì§€ìœ„ëŠ” ê¸€ë¡œë²Œ ê¸°ì¤€ìœ¼ë¡œ ì•ˆì •ì ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>While early TAVR studied TAVR AS patients without symptom, we are encouraged by the impact this study has had on increasing the sense of urgency for the treatment of patients who have symptoms. The timely referral evaluation and treatment of patients with severe aortic stenosis is fueled by a large and growing body of evidence on the long-term outcomes of SAPIEN valves. Our position as the only TAVR therapy with asymptomatic indication will provide additional benefits along with the potential of an updated TAVR NCD and U.S. and Japan guideline evolution. These additive catalysts provide multiple layers of durable growth.</td><td>ì´ˆê¸° TAVR ì—°êµ¬ê°€ ë¬´ì¦ìƒ AS í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í–ˆì§€ë§Œ, ìš°ë¦¬ëŠ” ì´ ì—°êµ¬ê°€ ì¦ìƒì´ ìˆëŠ” í™˜ì ì¹˜ë£Œì˜ ê¸´ê¸‰ì„±ì— ëŒ€í•œ ì¸ì‹ì„ ë†’ì´ëŠ” ë° ë¯¸ì¹œ ì˜í–¥ì— ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì¤‘ì¦ ëŒ€ë™ë§¥ í˜‘ì°©ì¦ í™˜ìì˜ ì ì‹œ ì˜ë¢°, í‰ê°€ ë° ì¹˜ë£ŒëŠ” SAPIEN íŒë§‰ì˜ ì¥ê¸° ê²°ê³¼ì— ëŒ€í•œ ë°©ëŒ€í•˜ê³  ì¦ê°€í•˜ëŠ” ì¦ê±° ìë£Œì— ì˜í•´ ì´‰ì§„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬´ì¦ìƒ ì ì‘ì¦ì„ ê°€ì§„ ìœ ì¼í•œ TAVR ì¹˜ë£Œì œë¡œì„œì˜ ìš°ë¦¬ ì…ì§€ëŠ” ì—…ë°ì´íŠ¸ë  TAVR NCD(êµ­ê°€ë³´í—˜ì ìš©ê²°ì •)ì™€ ë¯¸êµ­ ë° ì¼ë³¸ ê°€ì´ë“œë¼ì¸ ê°œì • ê°€ëŠ¥ì„±ê³¼ í•¨ê»˜ ì¶”ê°€ì ì¸ ì´ì ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë¶€ê°€ì  ì´‰ë§¤ì œë“¤ì€ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì˜ ì—¬ëŸ¬ ì¸µì„ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>In addition to the long-term data presented at TCT, more than 30 distinguished physician thought leaders published the first ever AS global consensus document. This validates the movement away from the outdated practice of watchful waiting and further supports the importance of guideline management of CV AS patients. Let me turn to some U.S. commentary. We saw intentional and urgent treatment of severe aortic stenosis patients, fueled by a large and growing body of world-class evidence on the SAPIEN platform and the increased adoption of SAPIEN 3 Ultra RESILIA. We are pleased that CMS formally opened the process to reconsider the NCD for TAVR.</td><td>TCTì—ì„œ ë°œí‘œëœ ì¥ê¸° ë°ì´í„° ì™¸ì—ë„, 30ëª… ì´ìƒì˜ ì €ëª…í•œ ì˜ì‚¬ ì˜¤í”¼ë‹ˆì–¸ ë¦¬ë”ë“¤ì´ ì‚¬ìƒ ìµœì´ˆì˜ AS ê¸€ë¡œë²Œ ì»¨ì„¼ì„œìŠ¤ ë¬¸ì„œë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” êµ¬ì‹ ê´€í–‰ì¸ ê²½ê³¼ ê´€ì°°(watchful waiting)ì—ì„œ ë²—ì–´ë‚˜ëŠ” ì›€ì§ì„ì„ ê²€ì¦í•˜ê³ , CV AS í™˜ìë“¤ì— ëŒ€í•œ ê°€ì´ë“œë¼ì¸ ê´€ë¦¬ì˜ ì¤‘ìš”ì„±ì„ ë”ìš± ë’·ë°›ì¹¨í•©ë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ì— ëŒ€í•œ ì½”ë©˜íŠ¸ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” SAPIEN í”Œë«í¼ì— ëŒ€í•œ ë°©ëŒ€í•˜ê³  ì¦ê°€í•˜ëŠ” ì„¸ê³„ì  ìˆ˜ì¤€ì˜ ì„ìƒ ê·¼ê±°ì™€ SAPIEN 3 Ultra RESILIAì˜ ì±„íƒ ì¦ê°€ì— í˜ì…ì–´, ì¤‘ì¦ ëŒ€ë™ë§¥ í˜‘ì°©ì¦ í™˜ìë“¤ì— ëŒ€í•œ ì˜ë„ì ì´ê³  ì‹ ì†í•œ ì¹˜ë£Œë¥¼ ëª©ê²©í–ˆìŠµë‹ˆë‹¤. CMSê°€ TAVRì— ëŒ€í•œ NCDë¥¼ ì¬ê²€í† í•˜ëŠ” ì ˆì°¨ë¥¼ ê³µì‹ì ìœ¼ë¡œ ê°œì‹œí•œ ê²ƒì— ëŒ€í•´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>This decision has the potential to improve timely and equitable access to life-saving TAVR therapy. The initial 30-day public comment period closed on January 14 and we look forward to the process continuing. In Q4, we expanded our partnership with the American Heart Association as the founding sponsor of a heart valve initiative. This new initiative is focused on timely diagnosis and treatment to save lives and improve care for millions living with heart valve disease.</td><td>ì´ë²ˆ ê²°ì •ì€ ìƒëª…ì„ êµ¬í•˜ëŠ” TAVR ì¹˜ë£Œì— ëŒ€í•œ ì‹ ì†í•˜ê³  ê³µí‰í•œ ì ‘ê·¼ì„±ì„ ê°œì„ í•  ìˆ˜ ìˆëŠ” ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ˆê¸° 30ì¼ê°„ì˜ ê³µê°œ ì˜ê²¬ ìˆ˜ë ´ ê¸°ê°„ì´ 1ì›” 14ì¼ì— ì¢…ë£Œë˜ì—ˆìœ¼ë©°, ìš°ë¦¬ëŠ” ì´ ê³¼ì •ì´ ê³„ì† ì§„í–‰ë˜ê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ìš°ë¦¬ëŠ” ì‹¬ì¥íŒë§‰ ì´ë‹ˆì…”í‹°ë¸Œì˜ ì°½ë¦½ ìŠ¤í°ì„œë¡œì„œ ë¯¸êµ­ì‹¬ì¥í˜‘íšŒ(American Heart Association)ì™€ì˜ íŒŒíŠ¸ë„ˆì‹­ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. ì´ ìƒˆë¡œìš´ ì´ë‹ˆì…”í‹°ë¸ŒëŠ” ì‹¬ì¥íŒë§‰ ì§ˆí™˜ì„ ì•“ê³  ìˆëŠ” ìˆ˜ë°±ë§Œ ëª…ì˜ ìƒëª…ì„ êµ¬í•˜ê³  ì¹˜ë£Œë¥¼ ê°œì„ í•˜ê¸° ìœ„í•œ ì ì‹œ ì§„ë‹¨ê³¼ ì¹˜ë£Œì— ì¤‘ì ì„ ë‘ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It is a multiyear program to elevate heart valve disease as a critical focus area for hospital systems through adherence to specific quality metric based care, expanded data collection, enhanced health care professional education and patient engagement. In Europe, fourth quarter results reflected healthy underlying TAVR procedure growth as well as our consistent execution across the region. Updated guidelines from the European Society of Cardiology and the European Association for Cardiothoracic surgery are reshaping clinical discussions around proactive disease management and reinforcing the role of TAVR for a broader patient population.</td><td>ì´ëŠ” íŠ¹ì • í’ˆì§ˆ ì§€í‘œ ê¸°ë°˜ ì¹˜ë£Œ ì¤€ìˆ˜, í™•ëŒ€ëœ ë°ì´í„° ìˆ˜ì§‘, ê°•í™”ëœ ì˜ë£Œ ì „ë¬¸ê°€ êµìœ¡ ë° í™˜ì ì°¸ì—¬ë¥¼ í†µí•´ ì‹¬ì¥ íŒë§‰ ì§ˆí™˜ì„ ë³‘ì› ì‹œìŠ¤í…œì˜ í•µì‹¬ ì§‘ì¤‘ ì˜ì—­ìœ¼ë¡œ ê²©ìƒì‹œí‚¤ê¸° ìœ„í•œ ë‹¤ê°œë…„ í”„ë¡œê·¸ë¨ì…ë‹ˆë‹¤. ìœ ëŸ½ì˜ ê²½ìš°, 4ë¶„ê¸° ì‹¤ì ì€ ê²¬ê³ í•œ ê¸°ì € TAVR ì‹œìˆ  ì„±ì¥ê³¼ í•¨ê»˜ ì§€ì—­ ì „ë°˜ì— ê±¸ì¹œ ì¼ê´€ëœ ì‹¤í–‰ë ¥ì„ ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. ìœ ëŸ½ì‹¬ì¥í•™íšŒ(European Society of Cardiology)ì™€ ìœ ëŸ½ì‹¬ì¥í‰ë¶€ì™¸ê³¼í•™íšŒ(European Association for Cardiothoracic Surgery)ì˜ ì—…ë°ì´íŠ¸ëœ ê°€ì´ë“œë¼ì¸ì€ ì„ ì œì  ì§ˆí™˜ ê´€ë¦¬ì— ëŒ€í•œ ì„ìƒ ë…¼ì˜ë¥¼ ì¬í¸í•˜ê³  ìˆìœ¼ë©°, ë” ê´‘ë²”ìœ„í•œ í™˜ìêµ°ì— ëŒ€í•œ TAVRì˜ ì—­í• ì„ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also continue to see modest year-over-year share improvement in several key countries, strengthening our leadership position in the wake of a competitor's exit. In summary for TAVR, we are pleased with our strong Q4 results and full year 2025 performance. SAPIEN growth globally was supported by rising clinical urgency for intentional proactive disease management and long-term evidence demonstrating the proven durability and valve performance of SAPIEN 3.</td><td>ë˜í•œ ìš°ë¦¬ëŠ” ì—¬ëŸ¬ ì£¼ìš” êµ­ê°€ì—ì„œ ì „ë…„ ëŒ€ë¹„ ì™„ë§Œí•œ ì‹œì¥ì ìœ ìœ¨ ê°œì„ ì„ ì§€ì†ì ìœ¼ë¡œ í™•ì¸í•˜ê³  ìˆìœ¼ë©°, ê²½ìŸì‚¬ì˜ ì‹œì¥ ì² ìˆ˜ ì´í›„ ìš°ë¦¬ì˜ ì„ ë„ì  ì§€ìœ„ë¥¼ ë”ìš± ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. TAVR ë¶€ë¬¸ì„ ìš”ì•½í•˜ìë©´, ìš°ë¦¬ëŠ” ê°•ë ¥í•œ 4ë¶„ê¸° ì‹¤ì ê³¼ 2025ë…„ ì „ì²´ ì—°ê°„ ì„±ê³¼ì— ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. SAPIENì˜ ê¸€ë¡œë²Œ ì„±ì¥ì€ ì˜ë„ì ì´ê³  ì„ ì œì ì¸ ì§ˆí™˜ ê´€ë¦¬ì— ëŒ€í•œ ì„ìƒì  ê¸´ê¸‰ì„± ì¦ê°€ì™€ SAPIEN 3ì˜ ì…ì¦ëœ ë‚´êµ¬ì„± ë° íŒë§‰ ì„±ëŠ¥ì„ ë³´ì—¬ì£¼ëŠ” ì¥ê¸° ì„ìƒ ê·¼ê±°ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>As we look ahead, we are well positioned to continue the momentum and remain focused on driving our patient access strategy, generating additional clinical evidence and delivering on our innovation pipeline to address the growing patient needs across the world. These strengths reinforce our confidence in Edwards' TAVR as a durable growth engine and a meaningful contributor to long-term value creation. Now let's turn to our TMTT product group. Our comprehensive portfolio of repair and replacement therapies offers meaningful opportunities to physicians to best treat their mitral and tricuspid patients. This drove another strong quarter with TMTT growing over 40% to $156 million.</td><td>ì•ìœ¼ë¡œë¥¼ ì „ë§í•  ë•Œ, ìš°ë¦¬ëŠ” ëª¨ë©˜í…€ì„ ì§€ì†í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìœ¼ë©°, ì „ ì„¸ê³„ì ìœ¼ë¡œ ì¦ê°€í•˜ëŠ” í™˜ì ìˆ˜ìš”ë¥¼ í•´ê²°í•˜ê¸° ìœ„í•´ í™˜ì ì ‘ê·¼ì„± ì „ëµ ì¶”ì§„, ì¶”ê°€ ì„ìƒ ê·¼ê±° ìƒì„±, ê·¸ë¦¬ê³  í˜ì‹  íŒŒì´í”„ë¼ì¸ ì´í–‰ì— ê³„ì† ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°•ì ë“¤ì€ Edwardsì˜ TAVRì´ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ ë™ë ¥ì´ì ì¥ê¸°ì  ê°€ì¹˜ ì°½ì¶œì— ì˜ë¯¸ ìˆëŠ” ê¸°ì—¬ë¥¼ í•  ê²ƒì´ë¼ëŠ” ìš°ë¦¬ì˜ í™•ì‹ ì„ ë”ìš± ê°•í™”ì‹œí‚µë‹ˆë‹¤. ì´ì œ TMTT ì œí’ˆêµ°ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ í¬ê´„ì ì¸ ìˆ˜ë³µ ë° ì¹˜í™˜ ì¹˜ë£Œì œ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ì˜ì‚¬ë“¤ì´ ìŠ¹ëª¨íŒ ë° ì‚¼ì²¨íŒ í™˜ìë“¤ì„ ìµœì ìœ¼ë¡œ ì¹˜ë£Œí•  ìˆ˜ ìˆëŠ” ì˜ë¯¸ ìˆëŠ” ê¸°íšŒë¥¼ ì œê³µí•©ë‹ˆë‹¤. ì´ëŠ” ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ê²¬ì¸í–ˆìœ¼ë©°, TMTTëŠ” 40% ì´ìƒ ì„±ì¥í•˜ì—¬ 1ì–µ 5,600ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We were also pleased that for the full year, TMTT sales exceeded $0.5 billion. Continued global adoption of PASCAL and EVOQUE contributed to overall growth. Physicians continue to provide positive feedback on PASCAL's differentiated benefits for treatment of their patients who need transcatheter edge-to-edge repair. With EVOQUE, we are expanding the number of centers and training more physicians while focusing on excellent patient outcomes. The recent FDA approval of SAPIEN M3 expands our mitral portfolio in the U.S. and represents the first transcatheter replacement option suffering from mitral disease.</td><td>ë˜í•œ ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ TMTT ë§¤ì¶œì´ 5ì–µ ë‹¬ëŸ¬ë¥¼ ì´ˆê³¼í•œ ê²ƒì— ëŒ€í•´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. PASCALê³¼ EVOQUEì˜ ì§€ì†ì ì¸ ê¸€ë¡œë²Œ ì±„íƒì´ ì „ì²´ ì„±ì¥ì— ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ì˜ë£Œì§„ë“¤ì€ ê²½ì¹´í…Œí„° ì—£ì§€-íˆ¬-ì—£ì§€ ë³µì›ìˆ (transcatheter edge-to-edge repair)ì´ í•„ìš”í•œ í™˜ì ì¹˜ë£Œì— ìˆì–´ PASCALì˜ ì°¨ë³„í™”ëœ ì´ì ì— ëŒ€í•´ ì§€ì†ì ìœ¼ë¡œ ê¸ì •ì ì¸ í”¼ë“œë°±ì„ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. EVOQUEì˜ ê²½ìš°, ìš°ìˆ˜í•œ í™˜ì ì¹˜ë£Œ ê²°ê³¼ì— ì¤‘ì ì„ ë‘ë©´ì„œ ì„¼í„° ìˆ˜ë¥¼ í™•ëŒ€í•˜ê³  ë” ë§ì€ ì˜ë£Œì§„ì„ êµìœ¡í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìµœê·¼ FDAì˜ SAPIEN M3 ìŠ¹ì¸ì€ ë¯¸êµ­ ë‚´ ìŠ¹ëª¨íŒ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™•ëŒ€í•˜ëŠ” ê²ƒì´ë©°, ìŠ¹ëª¨íŒ ì§ˆí™˜(mitral disease)ìœ¼ë¡œ ê³ í†µë°›ëŠ” í™˜ìë“¤ì„ ìœ„í•œ ìµœì´ˆì˜ ê²½ì¹´í…Œí„° ëŒ€ì²´ ì˜µì…˜ì„ ì˜ë¯¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Similar to our other therapy launches, the strategic introduction of SAPIEN M3 is leveraging our proven high-value support model and focusing on outstanding clinical outcomes. We are initially opening sites that were previously in our ENCIRCLE pivotal clinical trials and physician interest in this technology is growing. With PASCAL and EVOQUE globally and now with the introduction of SAPIEN M3 in the U.S. and Europe, Edwards continues to deliver on our vision of offering a portfolio of therapies to treat more mitral and tricuspid patients. Overall, PASCAL adoption globally is delivering differentiated outcome for patients.</td><td>ë‹¤ë¥¸ ì¹˜ë£Œë²• ì¶œì‹œì™€ ë§ˆì°¬ê°€ì§€ë¡œ, SAPIEN M3ì˜ ì „ëµì  ë„ì…ì€ ê²€ì¦ëœ ê³ ë¶€ê°€ê°€ì¹˜ ì§€ì› ëª¨ë¸ì„ í™œìš©í•˜ê³  ìˆìœ¼ë©° íƒì›”í•œ ì„ìƒ ê²°ê³¼ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ˆê¸°ì—ëŠ” ì´ì „ì— ENCIRCLE ì¤‘ì¶” ì„ìƒì‹œí—˜ì— ì°¸ì—¬í–ˆë˜ ê¸°ê´€ë“¤ì„ ì¤‘ì‹¬ìœ¼ë¡œ ê°œì„¤í•˜ê³  ìˆìœ¼ë©°, ì´ ê¸°ìˆ ì— ëŒ€í•œ ì˜ì‚¬ë“¤ì˜ ê´€ì‹¬ì´ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ ì„¸ê³„ì ìœ¼ë¡œ PASCALê³¼ EVOQUE, ê·¸ë¦¬ê³  ì´ì œ ë¯¸êµ­ê³¼ ìœ ëŸ½ì—ì„œ SAPIEN M3ì˜ ë„ì…ìœ¼ë¡œ, EdwardsëŠ” ë” ë§ì€ ìŠ¹ëª¨íŒë§‰ ë° ì‚¼ì²¨íŒë§‰ í™˜ìë¥¼ ì¹˜ë£Œí•˜ê¸° ìœ„í•œ ì¹˜ë£Œë²• í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì œê³µí•˜ê² ë‹¤ëŠ” ë¹„ì „ì„ ì§€ì†ì ìœ¼ë¡œ ì‹¤í˜„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ PASCALì˜ ì „ ì„¸ê³„ì  ë„ì…ì€ í™˜ìë“¤ì—ê²Œ ì°¨ë³„í™”ëœ ê²°ê³¼ë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The introduction of next gen PASCAL in Q4 will further distinguish this important therapy for patients who need edge-to-edge repair. The upcoming U.S. approval of PASCAL for tricuspid patients will provide an enhanced therapy alternative. And the scaling of EVOQUE and launch of SAPIEN M3 will further advance treatment for tricuspid and mitral patients. This represents multiyear growth opportunities starting in 2026 and contributing to achieving $2 billion of revenue in 2030 and additional growth beyond. Finally, this year, we continue to expect sales in the range of $740 million to $780 million.</td><td>4ë¶„ê¸°ì— ì°¨ì„¸ëŒ€ PASCALì˜ ì¶œì‹œëŠ” edge-to-edge ì¹˜ë£Œê°€ í•„ìš”í•œ í™˜ìë“¤ì„ ìœ„í•œ ì´ ì¤‘ìš”í•œ ì¹˜ë£Œë²•ì„ ë”ìš± ì°¨ë³„í™”í•  ê²ƒì…ë‹ˆë‹¤. ê³§ ìˆì„ ì‚¼ì²¨íŒ í™˜ìë¥¼ ìœ„í•œ PASCALì˜ ë¯¸êµ­ ìŠ¹ì¸ì€ í–¥ìƒëœ ì¹˜ë£Œ ëŒ€ì•ˆì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  EVOQUEì˜ í™•ëŒ€ì™€ SAPIEN M3ì˜ ì¶œì‹œëŠ” ì‚¼ì²¨íŒ ë° ìŠ¹ëª¨íŒ í™˜ìë“¤ì„ ìœ„í•œ ì¹˜ë£Œë¥¼ ë”ìš± ë°œì „ì‹œí‚¬ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” 2026ë…„ë¶€í„° ì‹œì‘í•˜ì—¬ 2030ë…„ ë§¤ì¶œ 20ì–µ ë‹¬ëŸ¬ ë‹¬ì„±ì— ê¸°ì—¬í•˜ê³  ê·¸ ì´í›„ì—ë„ ì¶”ê°€ ì„±ì¥ì„ ì´ì–´ê°ˆ ìˆ˜ ìˆëŠ” ë‹¤ë…„ê°„ì˜ ì„±ì¥ ê¸°íšŒë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì˜¬í•´ ë§¤ì¶œì€ 7ì–µ 4ì²œë§Œ ë‹¬ëŸ¬ì—ì„œ 7ì–µ 8ì²œë§Œ ë‹¬ëŸ¬ ë²”ìœ„ë¥¼ ì§€ì†ì ìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In our Surgical product group, fourth quarter global sales of $254 million increased 2% over the prior year. The underlying fundamentals of our Surgical product group remains strong while growth in Q4 was impacted by end of year distributor inventory adjustments in one country. Full year surgical sales grew 4.3% and for the first time, exceeded $1 billion. We continue to expect mid-single-digit sales growth rate in Surgical in 2026, driven by continued adoption of our RESILIA therapies that offer extended durability of our surgical therapies, including INSPIRIS, KONECT and MITRIS.</td><td>ë‹¹ì‚¬ì˜ ì™¸ê³¼ ì œí’ˆêµ°(Surgical product group)ì—ì„œ 4ë¶„ê¸° ê¸€ë¡œë²Œ ë§¤ì¶œì€ 2ì–µ 5,400ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 2% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì™¸ê³¼ ì œí’ˆêµ°ì˜ ê¸°ë³¸ì ì¸ í€ë”ë©˜í„¸ì€ ê²¬ì¡°í•˜ê²Œ ìœ ì§€ë˜ê³  ìˆìœ¼ë‚˜, 4ë¶„ê¸° ì„±ì¥ë¥ ì€ í•œ êµ­ê°€ì—ì„œì˜ ì—°ë§ ìœ í†µì—…ì²´ ì¬ê³  ì¡°ì •ìœ¼ë¡œ ì¸í•´ ì˜í–¥ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ì—°ê°„ ì™¸ê³¼ ë§¤ì¶œì€ 4.3% ì„±ì¥í–ˆìœ¼ë©°, ì²˜ìŒìœ¼ë¡œ 10ì–µ ë‹¬ëŸ¬ë¥¼ ëŒíŒŒí–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” INSPIRIS, KONECT, MITRISë¥¼ í¬í•¨í•œ ì™¸ê³¼ ì¹˜ë£Œì œì˜ ë‚´êµ¬ì„±ì„ ì—°ì¥í•˜ëŠ” RESILIA ì¹˜ë£Œë²•ì˜ ì§€ì†ì ì¸ ì±„íƒì— í˜ì…ì–´ 2026ë…„ ì™¸ê³¼ ë¶€ë¬¸ì—ì„œ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜(mid-single-digit) ë§¤ì¶œ ì„±ì¥ë¥ ì„ ì§€ì†ì ìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We were encouraged by new data presented at the recent STS meeting, including strong 1-year data from the MOMENTIS study. MOMENTIS is studying long-term durability for the Edwards' MITRIS systems for surgical mitral valve replacement and 1-year result from the study demonstrated 100% freedom from SVD, impressive stable hemodynamic performance and excellent safety. This specifically designed surgical valve customized for mitral patients will advance and improve care. We are also pursuing multiple new innovation to advance surgical solutions for patients, including left atrial appendage closure or LAAC.</td><td>ìµœê·¼ STS í•™íšŒì—ì„œ ë°œí‘œëœ ìƒˆë¡œìš´ ë°ì´í„°, íŠ¹íˆ MOMENTIS ì—°êµ¬ì˜ ê°•ë ¥í•œ 1ë…„ ë°ì´í„°ì— ê³ ë¬´ë˜ì—ˆìŠµë‹ˆë‹¤. MOMENTISëŠ” Edwardsì˜ MITRIS ì‹œìŠ¤í…œì„ ì´ìš©í•œ ì™¸ê³¼ì  ìŠ¹ëª¨íŒë§‰ ì¹˜í™˜ìˆ ì˜ ì¥ê¸° ë‚´êµ¬ì„±ì„ ì—°êµ¬í•˜ê³  ìˆìœ¼ë©°, 1ë…„ ì—°êµ¬ ê²°ê³¼ëŠ” SVD(êµ¬ì¡°ì  íŒë§‰ ì—´í™”)ë¡œë¶€í„° 100% ììœ ë¡œì›€, ì¸ìƒì ìœ¼ë¡œ ì•ˆì •ì ì¸ í˜ˆì—­í•™ì  ì„±ëŠ¥, ê·¸ë¦¬ê³  ìš°ìˆ˜í•œ ì•ˆì „ì„±ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ìŠ¹ëª¨íŒë§‰ í™˜ìë¥¼ ìœ„í•´ íŠ¹ë³„íˆ ì„¤ê³„ë˜ê³  ë§ì¶¤í™”ëœ ì´ ì™¸ê³¼ìš© íŒë§‰ì€ í™˜ì ì¹˜ë£Œë¥¼ ë°œì „ì‹œí‚¤ê³  ê°œì„ í•  ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” ì¢Œì‹¬ë°©ì´ íì‡„ìˆ (LAAC)ì„ í¬í•¨í•˜ì—¬ í™˜ìë¥¼ ìœ„í•œ ì™¸ê³¼ì  ì†”ë£¨ì…˜ì„ ë°œì „ì‹œí‚¤ê¸° ìœ„í•œ ì—¬ëŸ¬ ìƒˆë¡œìš´ í˜ì‹ ì„ ì¶”êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is a new therapeutic area that is a complementary solution to specific valvular procedures and we are planning on a preliminary introduction of our new surgical LAAC technology later this year. In summary, we still expect to deliver our mid-single-digit sales growth rate guidance in 2026. And finally, we are looking forward to seeing 10-year data from our COMMENCE trial at the ATS conference in May, studying long-term durability of our best-in-class RESILIA tissue. And now Scott will cover the details of the company's financial performance. Scott Ullem<br>Corporate VP & CFO<br><br>Thanks, Bernard.</td><td>ì´ê²ƒì€ íŠ¹ì • íŒë§‰ ì‹œìˆ ì— ëŒ€í•œ ë³´ì™„ì  ì†”ë£¨ì…˜ì¸ ìƒˆë¡œìš´ ì¹˜ë£Œ ì˜ì—­ì´ë©°, ì˜¬í•´ í›„ë°˜ì— ìƒˆë¡œìš´ ìˆ˜ìˆ ìš© LAAC ê¸°ìˆ ì„ ì˜ˆë¹„ ì¶œì‹œí•  ê³„íšì…ë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, ìš°ë¦¬ëŠ” ì—¬ì „íˆ 2026ë…„ ì¤‘ë°˜ í•œ ìë¦¿ìˆ˜ ë§¤ì¶œ ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìš°ë¦¬ëŠ” 5ì›” ATS ì»¨í¼ëŸ°ìŠ¤ì—ì„œ COMMENCE ì„ìƒì‹œí—˜ì˜ 10ë…„ ë°ì´í„°ë¥¼ ë°œí‘œí•  ê²ƒì„ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ RESILIA ì¡°ì§ì˜ ì¥ê¸° ë‚´êµ¬ì„±ì„ ì—°êµ¬í•œ ê²ƒì…ë‹ˆë‹¤. ì´ì œ Scottì´ íšŒì‚¬ì˜ ì¬ë¬´ ì„±ê³¼ì— ëŒ€í•œ ì„¸ë¶€ ì‚¬í•­ì„ ì„¤ëª…í•˜ê² ìŠµë‹ˆë‹¤.<br><br>Scott Ullem<br>ê¸°ì—… ë¶€ì‚¬ì¥ ê²¸ CFO<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Bernard.</td></tr>
<tr><td>Today, I will provide a wrap-up of 2025, including detailed results of our fourth quarter and guidance for the first quarter and full year 2026. We were pleased with our better-than-expected Q4 sales performance with strength across all product groups. Total sales of $1.57 billion grew 11.6% year-over-year. Our adjusted earnings per share was $0.58, this lower-than-expected EPS was driven by higher spending on patient access initiatives and a higher-than-expected tax rate. It is important to note that we have increased confidence in our 2026 earnings per share guidance of $2.90 to $3.05.</td><td>ì˜¤ëŠ˜ì€ 4ë¶„ê¸° ìƒì„¸ ì‹¤ì ê³¼ 2026ë…„ 1ë¶„ê¸° ë° ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ í¬í•¨í•œ 2025ë…„ ì´ê´„ ë‚´ìš©ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ëª¨ë“  ì œí’ˆêµ°ì—ì„œ ê°•ì„¸ë¥¼ ë³´ì´ë©° ì˜ˆìƒì„ ìƒíšŒí•œ 4ë¶„ê¸° ë§¤ì¶œ ì‹¤ì ì— ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì´ë§¤ì¶œì€ 15ì–µ 7ì²œë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 11.6% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ 0.58ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŸ¬í•œ ì˜ˆìƒì¹˜ í•˜íšŒ EPSëŠ” í™˜ì ì ‘ê·¼ì„± ê°œì„  ì‚¬ì—…ì— ëŒ€í•œ ì§€ì¶œ ì¦ê°€ì™€ ì˜ˆìƒë³´ë‹¤ ë†’ì€ ì„¸ìœ¨ì— ê¸°ì¸í–ˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€ ë‹¹ì‚¬ê°€ 2026ë…„ ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ì¸ 2.90ë‹¬ëŸ¬ì—ì„œ 3.05ë‹¬ëŸ¬ì— ëŒ€í•´ í™•ì‹ ì´ ë†’ì•„ì¡Œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our GAAP EPS for the quarter was $0.11, which included onetime charges related to the JenaValve acquisition that did not close as well as litigation expenses. A full reconciliation between our GAAP and adjusted EPS for this and other items is included with today's release. And now I'll cover additional details of our P&L. For the fourth quarter, our adjusted gross profit margin was 78.3%, in line with our expectations compared to 79.0% in the same period last year. This expected year-over-year change was driven by additional manufacturing expenses related to the fast expansion of new therapies.</td><td>ë‹¹ì‚¬ì˜ 4ë¶„ê¸° GAAP ì£¼ë‹¹ìˆœì´ìµì€ 0.11ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì—¬ê¸°ì—ëŠ” ì„±ì‚¬ë˜ì§€ ì•Šì€ JenaValve ì¸ìˆ˜ ê´€ë ¨ ì¼íšŒì„± ë¹„ìš©ê³¼ ì†Œì†¡ ë¹„ìš©ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ê±´ê³¼ ê¸°íƒ€ í•­ëª©ë“¤ì— ëŒ€í•œ GAAPì™€ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ê°„ì˜ ì „ì²´ ì¡°ì •ë‚´ì—­ì€ ì˜¤ëŠ˜ ë°œí‘œìë£Œì— í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ì œ ì†ìµê³„ì‚°ì„œì˜ ì¶”ê°€ ì„¸ë¶€ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ 78.3%ë¡œ ë‹¹ì‚¬ì˜ ì˜ˆìƒì¹˜ì— ë¶€í•©í–ˆìœ¼ë©°, ì „ë…„ ë™ê¸° 79.0%ì™€ ë¹„êµë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì „ë…„ ëŒ€ë¹„ ë³€í™”ëŠ” ì˜ˆìƒëœ ê²ƒìœ¼ë¡œ, ì‹ ê·œ ì¹˜ë£Œë²•ì˜ ë¹ ë¥¸ í™•ëŒ€ì™€ ê´€ë ¨ëœ ì¶”ê°€ ì œì¡°ë¹„ìš©ì— ê¸°ì¸í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We continue to expect our full year 2026 adjusted gross profit margin to be within our original guidance range of 78% to 79%. Selling, general and administrative expense in the quarter was $603 million or 38% of sales compared to 35% of sales in the prior year. We increased SG&A spending in the fourth quarter to fund strategic investments in order to amplify patient access to therapy, such as early TAVR education, investment in field resources and the AHA heart valve initiative. Some of the strategic spending was delayed from previous quarters in the year.</td><td>ë‹¹ì‚¬ëŠ” 2026 íšŒê³„ì—°ë„ ì „ì²´ ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì´ ê¸°ì¡´ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì¸ 78%~79% ë‚´ì— ìˆì„ ê²ƒìœ¼ë¡œ ê³„ì† ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ë¶„ê¸° íŒë§¤ê´€ë¦¬ë¹„ëŠ” 6ì–µ 3ë°±ë§Œ ë‹¬ëŸ¬ë¡œ ë§¤ì¶œì˜ 38%ë¥¼ ì°¨ì§€í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ë„ ë§¤ì¶œì˜ 35%ì™€ ë¹„êµë©ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 4ë¶„ê¸°ì— ì¡°ê¸° TAVR êµìœ¡, í˜„ì¥ ì¸ë ¥ íˆ¬ì, AHA ì‹¬ì¥íŒë§‰ ì´ë‹ˆì…”í‹°ë¸Œ ë“± í™˜ìì˜ ì¹˜ë£Œ ì ‘ê·¼ì„±ì„ í™•ëŒ€í•˜ê¸° ìœ„í•œ ì „ëµì  íˆ¬ì ì¬ì›ì„ ë§ˆë ¨í•˜ê³ ì íŒë§¤ê´€ë¦¬ë¹„ ì§€ì¶œì„ ì¦ê°€ì‹œì¼°ìŠµë‹ˆë‹¤. ì¼ë¶€ ì „ëµì  ì§€ì¶œì€ ì—°ì¤‘ ì´ì „ ë¶„ê¸°ì—ì„œ ì§€ì—°ëœ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Research and development expense was $268 million in the fourth quarter or 17.1% of sales compared to $271 million or 19.6% of sales in the same period last year. This decrease in R&D as a percentage of sales reflects our strategic prioritization of investments in our expanding structural heart portfolio. We continue to expect 2026 R&D as a percentage of sales to be approximately 17%. Fourth quarter adjusted operating profit margin of 23.7% was aligned with our previous guidance of mid-20%. Our full year 2025 adjusted operating profit margin of 27% was within our original expectations for the year.</td><td>4ë¶„ê¸° ì—°êµ¬ê°œë°œë¹„ëŠ” 2ì–µ 6,800ë§Œ ë‹¬ëŸ¬ë¡œ ë§¤ì¶œì˜ 17.1%ë¥¼ ì°¨ì§€í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ ë™ê¸° 2ì–µ 7,100ë§Œ ë‹¬ëŸ¬(ë§¤ì¶œì˜ 19.6%)ì™€ ë¹„êµë©ë‹ˆë‹¤. ë§¤ì¶œ ëŒ€ë¹„ R&D ë¹„ìœ¨ì˜ ê°ì†ŒëŠ” í™•ì¥ ì¤‘ì¸ êµ¬ì¡°ì  ì‹¬ì¥ì§ˆí™˜(structural heart) í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•œ íˆ¬ìì˜ ì „ëµì  ìš°ì„ ìˆœìœ„ ì¡°ì •ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2026ë…„ ë§¤ì¶œ ëŒ€ë¹„ R&D ë¹„ìœ¨ì´ ì•½ 17% ìˆ˜ì¤€ì„ ìœ ì§€í•  ê²ƒìœ¼ë¡œ ê³„ì† ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ 23.7%ë¡œ ê¸°ì¡´ ê°€ì´ë˜ìŠ¤ì¸ 20% ì¤‘ë°˜ëŒ€ì™€ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. 2025ë…„ ì „ì²´ ì—°ë„ ì¡°ì • ì˜ì—…ì´ìµë¥  27%ëŠ” ì—°ì´ˆ ì˜ˆìƒ ë²”ìœ„ ë‚´ì— ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For 2026, we expect approximately 150 basis points constant currency operating margin expansion, which includes less spending related to removing JenaValve from our operating plans for the year. We continue to plan for 50 to 100 basis points of operating margin expansion annually on average in 2027 and beyond. We continue to plan to deliver leveraged earnings per share. Turning to taxes. Our reported tax rate this quarter was 29% or 17.9%, excluding the impact of special items, which was above our expectation for the quarter, driven by Pillar Two impact and country income mix. We continue to expect our 2026 tax rate, excluding special items, to be between 16% and 19%.</td><td>2026ë…„ì—ëŠ” ì•½ 150bpì˜ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ ì˜ì—…ì´ìµë¥  ê°œì„ ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” JenaValveë¥¼ ì—°ê°„ ìš´ì˜ ê³„íšì—ì„œ ì œì™¸í•¨ì— ë”°ë¥¸ ì§€ì¶œ ê°ì†Œë¥¼ í¬í•¨í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. 2027ë…„ ì´í›„ì—ë„ ì—°í‰ê·  50~100bpì˜ ì˜ì—…ì´ìµë¥  ê°œì„ ì„ ì§€ì†ì ìœ¼ë¡œ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. ë ˆë²„ë¦¬ì§€ íš¨ê³¼ê°€ ë°˜ì˜ëœ ì£¼ë‹¹ìˆœì´ìµ ë‹¬ì„±ì„ ì§€ì†ì ìœ¼ë¡œ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì„¸ê¸ˆìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ë³´ê³ ëœ ì„¸ìœ¨ì€ 29%ì˜€ìœ¼ë©°, íŠ¹ë³„í•­ëª©ì„ ì œì™¸í•˜ë©´ 17.9%ë¡œ ë¶„ê¸° ì˜ˆìƒì¹˜ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” Pillar Twoì˜ ì˜í–¥ê³¼ êµ­ê°€ë³„ ì†Œë“ êµ¬ì„±ì— ê¸°ì¸í•©ë‹ˆë‹¤. íŠ¹ë³„í•­ëª©ì„ ì œì™¸í•œ 2026ë…„ ì„¸ìœ¨ì€ 16%ì—ì„œ 19% ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ê³„ì† ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Turning to the balance sheet. We continue to maintain a strong and flexible balance sheet with approximately $3 billion in cash and cash equivalents as of December 31. Edwards currently has approximately $2 billion remaining under its share repurchase authorization. Average diluted shares outstanding during the quarter were 582 million. We continue to expect average diluted shares outstanding for 2026 to be between 580 million to 585 million. Foreign exchange rates increased fourth quarter reported sales growth by 170 basis points or $20 million compared to the prior year. FX rates had minimal impact on our fourth quarter gross profit margin compared to the prior year.</td><td>ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ì‚´í´ë³´ë©´, 12ì›” 31ì¼ ê¸°ì¤€ ì•½ 30ì–µ ë‹¬ëŸ¬ì˜ í˜„ê¸ˆ ë° í˜„ê¸ˆì„±ìì‚°ì„ ë³´ìœ í•˜ë©° ê°•ë ¥í•˜ê³  ìœ ì—°í•œ ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ì§€ì†ì ìœ¼ë¡œ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. EdwardsëŠ” í˜„ì¬ ìì‚¬ì£¼ ë§¤ì… ìŠ¹ì¸ í•œë„ ì¤‘ ì•½ 20ì–µ ë‹¬ëŸ¬ê°€ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤. ë‹¹ ë¶„ê¸° í‰ê·  í¬ì„ì£¼ì‹ìˆ˜ëŠ” 5ì–µ 8,200ë§Œ ì£¼ì˜€ìŠµë‹ˆë‹¤. 2026ë…„ í‰ê·  í¬ì„ì£¼ì‹ìˆ˜ëŠ” 5ì–µ 8,000ë§Œ ì£¼ì—ì„œ 5ì–µ 8,500ë§Œ ì£¼ ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ê³„ì† ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì™¸í™˜í™˜ìœ¨ì€ ì „ë…„ ëŒ€ë¹„ 4ë¶„ê¸° ë³´ê³  ë§¤ì¶œ ì„±ì¥ë¥ ì„ 170bp ë˜ëŠ” 2,000ë§Œ ë‹¬ëŸ¬ ì¦ê°€ì‹œì¼°ìŠµë‹ˆë‹¤. ì™¸í™˜í™˜ìœ¨ì€ ì „ë…„ ëŒ€ë¹„ 4ë¶„ê¸° ë§¤ì¶œì´ì´ìµë¥ ì— ë¯¸ë¯¸í•œ ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Relative to our October guidance, FX rates had a nominal impact on fourth quarter earnings per share. At current rates, we now expect FX to have an approximately $40 million upside to full year 2026 sales compared to the prior year. I'll finish with comments related to our outlook. We have increased confidence in meeting our 2026 full year sales growth rate guidance of 8% to 10% and earnings per share guidance of $2.90 to $3.05. The product group sales guidance we provided at Investor conference remains unchanged. For the first quarter, we're projecting sales of $1.55 billion to $1.63 billion.</td><td>10ì›” ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ í™˜ìœ¨ ë³€ë™ì€ 4ë¶„ê¸° ì£¼ë‹¹ìˆœì´ìµì— ë¯¸ë¯¸í•œ ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤. í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ, 2026 íšŒê³„ì—°ë„ ì „ì²´ ë§¤ì¶œì— ì „ë…„ ëŒ€ë¹„ ì•½ 4ì²œë§Œ ë‹¬ëŸ¬ì˜ ê¸ì •ì  ì˜í–¥ì´ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì „ë§ì— ëŒ€í•œ ì½”ë©˜íŠ¸ë¡œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2026 íšŒê³„ì—°ë„ ì „ì²´ ë§¤ì¶œ ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ 8%~10% ë° ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ $2.90~$3.05 ë‹¬ì„±ì— ëŒ€í•œ í™•ì‹ ì´ ë†’ì•„ì¡ŒìŠµë‹ˆë‹¤. íˆ¬ìì ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ì œì‹œí•œ ì œí’ˆêµ°ë³„ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ëŠ” ë³€ë™ ì—†ì´ ìœ ì§€ë©ë‹ˆë‹¤. 1ë¶„ê¸°ì˜ ê²½ìš° ë§¤ì¶œì„ 15ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ì—ì„œ 16ì–µ 3ì²œë§Œ ë‹¬ëŸ¬ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect slightly higher growth rates in the first half of 2026, following unusual summer seasonality that benefited 2025. We are expecting adjusted EPS in Q1 of $0.70 to $0.76, representing mid-teens growth at the midpoint of that range. And with that, I'll pass it back to Bernard. Bernard Zovighian<br>CEO & Director<br><br>Thank you, Scott. In closing, we finished 2025 strong and achieved many lasting catalysts. We have increased confidence in our top line and bottom line guidance for 2026. Our strategy of focusing on structural heart is demonstrating impactful results for the company and the patients we serve and is positioning us for long-term sustainable growth and value creation.</td><td>2026ë…„ ìƒë°˜ê¸°ì—ëŠ” 2025ë…„ì— í˜¸ì¬ë¡œ ì‘ìš©í–ˆë˜ ë¹„ì •ìƒì ì¸ ì—¬ë¦„ ê³„ì ˆì„± íš¨ê³¼ ì´í›„ ì†Œí­ ë†’ì€ ì„±ì¥ë¥ ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ë¶„ê¸° ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì€ 0.70ë‹¬ëŸ¬ì—ì„œ 0.76ë‹¬ëŸ¬ë¡œ ì „ë§í•˜ë©°, ì´ëŠ” í•´ë‹¹ ë²”ìœ„ì˜ ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ 10%ëŒ€ ì¤‘ë°˜ì˜ ì„±ì¥ë¥ ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì´ìƒìœ¼ë¡œ Bernardì—ê²Œ ë‹¤ì‹œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Bernard Zovighian<br>ìµœê³ ê²½ì˜ì(CEO) ê²¸ ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Scott. ë§ˆë¬´ë¦¬í•˜ìë©´, ë‹¹ì‚¬ëŠ” 2025ë…„ì„ ê°•ë ¥í•˜ê²Œ ë§ˆê°í–ˆìœ¼ë©° ë§ì€ ì§€ì†ì ì¸ ì„±ì¥ ë™ë ¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. 2026ë…„ ë§¤ì¶œ ë° ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ í™•ì‹ ì´ ë†’ì•„ì¡ŒìŠµë‹ˆë‹¤. êµ¬ì¡°ì  ì‹¬ì¥ì§ˆí™˜ì— ì§‘ì¤‘í•˜ëŠ” ë‹¹ì‚¬ì˜ ì „ëµì€ íšŒì‚¬ì™€ ìš°ë¦¬ê°€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” í™˜ìë“¤ì—ê²Œ ì˜ë¯¸ ìˆëŠ” ì„±ê³¼ë¥¼ ì…ì¦í•˜ê³  ìˆìœ¼ë©°, ì¥ê¸°ì ìœ¼ë¡œ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ê³¼ ê°€ì¹˜ ì°½ì¶œì„ ìœ„í•œ ì…ì§€ë¥¼ ë‹¤ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With that, I will turn it back over to Gerianne. Unknown Executive<br><br>Thank you, Bernard. We're ready to take your questions. [Operator Instructions]</td><td>ê°ì‚¬í•©ë‹ˆë‹¤, Bernard. ì´ì œ ì§ˆë¬¸ì„ ë°›ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. [êµí™˜ì› ì•ˆë‚´] ì§ˆë¬¸ì´ ìˆìœ¼ì‹  ë¶„ë“¤ì€ ì•ˆë‚´ì— ë”°ë¼ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Edwards Lifesciences Q4 2025 ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì„±ê³¼<br>- **4ë¶„ê¸° ë§¤ì¶œ**: 15.7ì–µ ë‹¬ëŸ¬, ì „ë…„ ëŒ€ë¹„ 11.6% ì„±ì¥ (constant currency ê¸°ì¤€)<br>- **2025ë…„ ì „ì²´ ë§¤ì¶œ ì„±ì¥ë¥ **: 10.7%<br>- **ì¡°ì • EPS**: 0.58ë‹¬ëŸ¬ (í™˜ì ì ‘ê·¼ì„± íˆ¬ì í™•ëŒ€ ë° ë†’ì€ ì„¸ìœ¨ë¡œ ì˜ˆìƒì¹˜ í•˜íšŒ)<br>- **ì¡°ì • ì˜ì—…ì´ìµë¥ **: 23.7% (4ë¶„ê¸°), 27% (ì—°ê°„)<br>- **ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ **: 78.3% (4ë¶„ê¸°, ì „ë…„ 79.0%ì—ì„œ í•˜ë½)<br><br>## 2026ë…„ ê°€ì´ë˜ìŠ¤ ë° ì „ë§<br>- **ë§¤ì¶œ ì„±ì¥ë¥ **: 8~10% (constant currency ê¸°ì¤€, ë‹¬ì„± í™•ì‹  ê°•í™”)<br>- **EPS ê°€ì´ë˜ìŠ¤**: 2.90~3.05ë‹¬ëŸ¬ (ë‹¬ì„± í™•ì‹  ì¦ê°€)<br>- **1ë¶„ê¸° ë§¤ì¶œ ì˜ˆìƒ**: 15.5ì–µ~16.3ì–µ ë‹¬ëŸ¬<br>- **1ë¶„ê¸° ì¡°ì • EPS**: 0.70~0.76ë‹¬ëŸ¬ (ì¤‘ê°„ê°’ ê¸°ì¤€ mid-teens ì„±ì¥)<br>- **ì˜ì—…ì´ìµë¥ **: ì•½ 150bp ê°œì„  ì˜ˆìƒ (constant currency ê¸°ì¤€)<br><br>## ì‚¬ì—…ë¶€ë¬¸ë³„ ì‹¤ì <br>- **TAVR**: 11.6ì–µ ë‹¬ëŸ¬ (10.6% ì„±ì¥), SAPIEN í”Œë«í¼ì˜ ì¥ê¸° ë‚´êµ¬ì„± ë°ì´í„°ì™€ EARLY TAVR ì„ìƒì‹œí—˜ ê²°ê³¼ê°€ ì„±ì¥ ê²¬ì¸<br>- **TMTT**: 1.56ì–µ ë‹¬ëŸ¬ (40% ì´ìƒ ì„±ì¥), ì—°ê°„ 5ì–µ ë‹¬ëŸ¬ ëŒíŒŒ.</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question comes from Robbie Marcus with JPMorgan.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ JPëª¨ê±´ì˜ ë¡œë¹„ ë§ˆì»¤ìŠ¤ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Marcus: JPMorgan Chase & Co, Research Division Great. Congrats on a good quarter. Two for me. First, maybe just on TAVR, 10.6%, another very strong quarter. I would have to imagine you're taking some share even excluding the Boston Scientific exit. So maybe just speak to the strength you're seeing, the confidence in it and any regional differences? And just one thing, if you can talk to volumes versus sales. I imagine the delta's price, but I had some questions on that.</td><td>**Robert Marcus:** ì¢‹ìŠµë‹ˆë‹¤. ì¢‹ì€ ë¶„ê¸° ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € TAVR ê´€ë ¨í•´ì„œìš”, 10.6% ì„±ì¥ìœ¼ë¡œ ë˜ í•œ ë²ˆ ë§¤ìš° ê°•ë ¥í•œ ë¶„ê¸°ë¥¼ ë³´ë‚´ì…¨ìŠµë‹ˆë‹¤. ë³´ìŠ¤í„´ ì‚¬ì´ì–¸í‹°í”½ì˜ ì‹œì¥ ì² ìˆ˜ë¥¼ ì œì™¸í•˜ë”ë¼ë„ ì‹œì¥ ì ìœ ìœ¨ì„ ê°€ì ¸ê°€ê³  ê³„ì‹  ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°ìš”. í˜„ì¬ ë³´ê³  ê³„ì‹  ê°•ì„¸ì™€ ê·¸ì— ëŒ€í•œ í™•ì‹ , ê·¸ë¦¬ê³  ì§€ì—­ë³„ ì°¨ì´ê°€ ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  í•œ ê°€ì§€ë§Œ ë”, ë¬¼ëŸ‰ ëŒ€ë¹„ ë§¤ì¶œì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ ì°¨ì´ê°€ ê°€ê²© ë•Œë¬¸ì¸ ê²ƒ ê°™ì€ë°, ì´ ë¶€ë¶„ì— ëŒ€í•œ ì§ˆë¬¸ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Thanks, Robbie. Good afternoon, everyone. Yes, one is we are very pleased about the quarter overall in the year for Edwards. With regards to TAVR, very pleased about the quarter. Like you said, we're growing 10.6% year-over-year. And what we see is truly the results of our strategy here, where last year, we brought a very compelling evidence, EARLY TAVR, PARTNER III, 7 years, PARTNER II, 10 years. And all of this gave confidence. All of this also enabled a renewed focus on TAVR as a category and specifically the SAPIEN platform. So this is creating the physicians to talk more about TAVR, to talk more about SAPIEN. This is enabling a physician to treat their patients a little bit early. This is also enabling providers to prioritize TAVR. So it is all of that together, but I'm going to ask you, Dan, to give you more specific details about the quarter.</td><td>**CEO & Director:** ê°ì‚¬í•©ë‹ˆë‹¤, Robbie. ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì„¸ìš”. ë„¤, ë¨¼ì € ì´ë²ˆ ë¶„ê¸°ì™€ ì˜¬í•´ Edwardsì˜ ì „ë°˜ì ì¸ ì‹¤ì ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. TAVR ê´€ë ¨í•´ì„œë„ ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì— ëŒ€ë‹¨íˆ ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ì „ë…„ ëŒ€ë¹„ 10.6% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ ì „ëµì˜ ê²°ê³¼ë¼ê³  ë³¼ ìˆ˜ ìˆëŠ”ë°ìš”, ì‘ë…„ì— EARLY TAVR, PARTNER III 7ë…„ ë°ì´í„°, PARTNER II 10ë…„ ë°ì´í„° ë“± ë§¤ìš° ì„¤ë“ë ¥ ìˆëŠ” ì„ìƒ ê·¼ê±°ë“¤ì„ ì œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒë“¤ì´ ì‹ ë¢°ë¥¼ êµ¬ì¶•í–ˆê³ , TAVR ì¹´í…Œê³ ë¦¬ ì „ë°˜, íŠ¹íˆ SAPIEN í”Œë«í¼ì— ëŒ€í•œ ìƒˆë¡œìš´ ê´€ì‹¬ì„ ë¶ˆëŸ¬ì¼ìœ¼ì¼°ìŠµë‹ˆë‹¤. ì´ë¡œ ì¸í•´ ì˜ì‚¬ë“¤ì´ TAVRì— ëŒ€í•´, SAPIENì— ëŒ€í•´ ë” ë§ì´ ì´ì•¼ê¸°í•˜ê²Œ ë˜ì—ˆê³ , í™˜ìë“¤ì„ ì¡°ê¸ˆ ë” ì¡°ê¸°ì— ì¹˜ë£Œí•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìœ¼ë©°, ì˜ë£Œê¸°ê´€ë“¤ë„ TAVRë¥¼ ìš°ì„ ìˆœìœ„ì— ë‘ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ ì¢…í•©í•œ ë‚´ìš©ì¸ë°, Danì—ê²Œ ì´ë²ˆ ë¶„ê¸°ì— ëŒ€í•œ ë³´ë‹¤ êµ¬ì²´ì ì¸ ì„¸ë¶€ ì‚¬í•­ì„ ì„¤ëª…í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Yes. Thanks, Bernard. And Robbie, you're spot on, right? Like the overall procedural growth rate in the quarter was in the high single digit. And so there is a gap. And you're absolutely on the money as far as share gain and pricing contributing to that gap. Largely on the share perspective, I mean, the share gain that we had from the Boston Scientific exit, contributed a big chunk of that. We are pleased to see the stickiness of that share gain from quarter 3 to quarter 4. We took our piece of that. But most of the competitors in Europe also benefited from Boston's exit. I would say that we benefited about in line with our competitive position in the market. But if you look at globally, like overall, our competitive position remains relatively stable, I would say. I mean, for sure, we're not weaker in Q4 than we were in Q3. But another piece of this is S3UR penetration, right? And we continue to see very strong adoption of this outstanding platform, a lot of positive feedback from physicians. And so this is also contributing like you mentioned a little bit on the price side.</td><td>**Daniel Lippis:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Bernard. Robbie, ì •í™•í•˜ê²Œ ì§šìœ¼ì…¨ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì „ì²´ ì‹œìˆ  ì„±ì¥ë¥ ì€ í•œ ìë¦¿ìˆ˜ í›„ë°˜ëŒ€ì˜€ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê²©ì°¨ê°€ ì¡´ì¬í•˜ëŠ” ê²ƒì´ì£ . ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ì™€ ê°€ê²© ì±…ì •ì´ ê·¸ ê²©ì°¨ì— ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. <br><br>ì£¼ë¡œ ì ìœ ìœ¨ ì¸¡ë©´ì—ì„œ ë³´ë©´, Boston Scientificì˜ ì‹œì¥ ì² ìˆ˜ë¡œ ì¸í•œ ì ìœ ìœ¨ í™•ëŒ€ê°€ ìƒë‹¹ ë¶€ë¶„ì„ ì°¨ì§€í–ˆìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì—ì„œ 4ë¶„ê¸°ë¡œ ë„˜ì–´ê°€ë©´ì„œ ì´ëŸ¬í•œ ì ìœ ìœ¨ í™•ëŒ€ê°€ ì§€ì†ë˜ëŠ” ê²ƒì„ ë³´ê³  ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì €í¬ê°€ ê·¸ ì¤‘ ì¼ë¶€ë¥¼ ê°€ì ¸ê°”ì£ . í•˜ì§€ë§Œ ìœ ëŸ½ì˜ ëŒ€ë¶€ë¶„ ê²½ìŸì‚¬ë“¤ë„ Bostonì˜ ì² ìˆ˜ë¡œ í˜œíƒì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì‹œì¥ì—ì„œì˜ ê²½ìŸì  ìœ„ì¹˜ì— ë¶€í•©í•˜ëŠ” ìˆ˜ì¤€ìœ¼ë¡œ í˜œíƒì„ ë°›ì•˜ë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê¸€ë¡œë²Œ ì „ì²´ë¡œ ë³´ë©´, ìš°ë¦¬ì˜ ê²½ìŸì  ìœ„ì¹˜ëŠ” ìƒëŒ€ì ìœ¼ë¡œ ì•ˆì •ì ìœ¼ë¡œ ìœ ì§€ë˜ê³  ìˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í™•ì‹¤í•œ ê²ƒì€ 4ë¶„ê¸°ì— 3ë¶„ê¸°ë³´ë‹¤ ì•½í•´ì§€ì§€ ì•Šì•˜ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë˜ ë‹¤ë¥¸ ìš”ì¸ì€ S3UR ì¹¨íˆ¬ìœ¨ì…ë‹ˆë‹¤. ì´ ë›°ì–´ë‚œ í”Œë«í¼ì— ëŒ€í•œ ì±„íƒì´ ê³„ì†í•´ì„œ ë§¤ìš° ê°•í•˜ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆê³ , ì˜ì‚¬ë“¤ë¡œë¶€í„° ë§ì€ ê¸ì •ì ì¸ í”¼ë“œë°±ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ê°€ê²© ì¸¡ë©´ì—ì„œë„ ì´ê²ƒì´ ê¸°ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Marcus: JPMorgan Chase & Co, Research Division Great. Maybe, Scott, just if you could talk to the increased spend on market access, you highlighted in fourth quarter, step up in SG&A was roughly $100 million, which is pretty substantial. So maybe just dig into that, where did the spending go? And how should we think about that rolling in? Do we think of that as onetime cost?</td><td>**Robert Marcus:** ë„¤, ì¢‹ìŠµë‹ˆë‹¤. ìŠ¤ì½§, 4ë¶„ê¸°ì— ê°•ì¡°í•˜ì…¨ë˜ ì‹œì¥ ì ‘ê·¼ì„± ê´€ë ¨ ì§€ì¶œ ì¦ê°€ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? íŒë§¤ê´€ë¦¬ë¹„ê°€ ì•½ 1ì–µ ë‹¬ëŸ¬ ì¦ê°€í–ˆëŠ”ë°, ì´ëŠ” ìƒë‹¹íˆ í° ê·œëª¨ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤. ì§€ì¶œì´ ì–´ë””ì— ì‚¬ìš©ë˜ì—ˆë‚˜ìš”? ê·¸ë¦¬ê³  ì´ê²ƒì´ ì•ìœ¼ë¡œ ì–´ë–»ê²Œ ë°˜ì˜ë ì§€ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ì¼íšŒì„± ë¹„ìš©ìœ¼ë¡œ ë´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Scott Ullem: Corporate VP & CFO Yes. Thanks, Robbie. I appreciate the question. We had planned a step-up in the fourth quarter spending, and we decided to be aggressive in light of the reception we were getting to the things Bernard mentioned earlier, the asymptomatic trial, the 7-year results, the 10-year results. And so we intentionally upped their spending in the fourth quarter, $112 million year-over-year. We were still in operating margin terms in the area that we had expected for the fourth quarter. So we had said mid-20% and that was sort of in the range of where we came in. We invested more aggressively in patient access. So asymptomatic amplification. Bernard mentioned the American Heart Association partnership. We've also been reinforcing our field force in THV and also in TMTT. Some of the spending was delayed from earlier quarters in 2025. So following this elevated level of spending in Q4, we are planning a more moderated operating expense growth and SG&A expense growth in 2026, which is how we get to the operating margin guidance of the high end of our original 28% to 29%. The other benefit in that margin increase or margin expansion is the exclusion of the original spending that we had planned for JenaValve. Maybe, Dan, do you want to talk a little bit more about some of these initiatives?</td><td>**Scott Ullem:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, ë¡œë¹„. ì§ˆë¬¸ ì£¼ì…”ì„œ ê³ ë§™ìŠµë‹ˆë‹¤. ì €í¬ëŠ” 4ë¶„ê¸°ì— ì§€ì¶œ ì¦ê°€ë¥¼ ê³„íší–ˆì—ˆê³ , ë²„ë‚˜ë“œê°€ ì•ì„œ ì–¸ê¸‰í•œ ë¬´ì¦ìƒ ì„ìƒì‹œí—˜, 7ë…„ ê²°ê³¼, 10ë…„ ê²°ê³¼ ë“±ì— ëŒ€í•œ ì‹œì¥ì˜ ë°˜ì‘ì„ ê³ ë ¤í•´ ê³µê²©ì ìœ¼ë¡œ íˆ¬ìí•˜ê¸°ë¡œ ê²°ì •í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜ë„ì ìœ¼ë¡œ 4ë¶„ê¸° ì§€ì¶œì„ ì „ë…„ ëŒ€ë¹„ 1ì–µ 1,200ë§Œ ë‹¬ëŸ¬ ëŠ˜ë ¸ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ì˜ì—…ì´ìµë¥  ì¸¡ë©´ì—ì„œëŠ” 4ë¶„ê¸°ì— ì˜ˆìƒí–ˆë˜ ë²”ìœ„ ë‚´ì— ìˆì—ˆìŠµë‹ˆë‹¤. 20% ì¤‘ë°˜ëŒ€ë¥¼ ì œì‹œí–ˆì—ˆê³ , ì‹¤ì œë¡œë„ ê·¸ ë²”ìœ„ ì•ˆì—ì„œ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í™˜ì ì ‘ê·¼ì„±ì— ë”ìš± ì ê·¹ì ìœ¼ë¡œ íˆ¬ìí–ˆìŠµë‹ˆë‹¤. ë¬´ì¦ìƒ í™˜ìêµ° í™•ëŒ€ ë¶€ë¶„ì´ì£ . ë²„ë‚˜ë“œê°€ ì–¸ê¸‰í•œ ë¯¸êµ­ì‹¬ì¥í˜‘íšŒ íŒŒíŠ¸ë„ˆì‹­ë„ ìˆê³ ìš”. THVì™€ TMTT ë¶„ì•¼ì—ì„œë„ í˜„ì¥ ì¸ë ¥ì„ ê°•í™”í•´ì™”ìŠµë‹ˆë‹¤. 2025ë…„ ì´ˆë°˜ ë¶„ê¸°ì—ì„œ ì§€ì—°ë˜ì—ˆë˜ ì¼ë¶€ ì§€ì¶œì´ ìˆì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 4ë¶„ê¸°ì˜ ì´ëŸ¬í•œ ë†’ì€ ì§€ì¶œ ìˆ˜ì¤€ ì´í›„, 2026ë…„ì—ëŠ” ë³´ë‹¤ ì™„í™”ëœ ì˜ì—…ë¹„ìš© ë° íŒê´€ë¹„ ì¦ê°€ë¥¼ ê³„íší•˜ê³  ìˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ë‹¹ì´ˆ ì œì‹œí–ˆë˜ 28~29% ì˜ì—…ì´ìµë¥  ê°€ì´ë˜ìŠ¤ì˜ ìƒë‹¨ì„ ë‹¬ì„±í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì´ìµë¥  ì¦ê°€ ë˜ëŠ” ì´ìµë¥  í™•ëŒ€ì˜ ë˜ ë‹¤ë¥¸ ìš”ì¸ì€ JenaValveì— ëŒ€í•´ ê³„íší–ˆë˜ ê¸°ì¡´ ì§€ì¶œì´ ì œì™¸ëœë‹¤ëŠ” ì ì…ë‹ˆë‹¤. Dan, ì´ëŸ¬í•œ ì´ë‹ˆì…”í‹°ë¸Œë“¤ì— ëŒ€í•´ ì¢€ ë” ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Yes. I think like a couple of big ones here, right? So with the change in the European guidelines. This is the biggest shift that we've seen in over 10 years. And it's a real important shift from watchful waiting to intentional and urgent treatment of severe aortic stenosis earlier in the disease pathway. This is a big shift. It involves change management and change of behavior, particularly at the referral level. And so we see an opportunity here to bend the curve of adoption of these guideline changes. And so we have a number of significant amplification programs that we have started and started to implement in Europe. This is a big one. Second one, as Scott and Bernard mentioned, our partnership with the AHA. This is an important one, and this is a multiyear partnership, and it's designed to do the same thing, democratize and educate on the importance of treating earlier in the disease pathway for aortic stenosis. And so this is all designed to improve diagnosis and treatment of severe AS through guideline-based care, through extended data collection, but also heavy on education. And so these are two big ones. We also invested further in some of the sort of short-range pilot stage marketing programs to improve treatment rates and patient and referral education in the United States and like Scott said, there are some field -- we're very much a high-touch field clinical field force and with volumes increasing, we need to get ahead of those resources in the field. They take time. They take time to train and get people certified. So we got ahead a little bit of that, but also a big chunk we got behind early in the year and a lot of that caught up with us in Q4. So they are the big items.</td><td>**Daniel Lippis:** ë„¤, ëª‡ ê°€ì§€ ì¤‘ìš”í•œ ì‚¬í•­ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë¨¼ì € ìœ ëŸ½ ê°€ì´ë“œë¼ì¸ ë³€ê²½ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì´ë²ˆ ë³€í™”ëŠ” ì§€ë‚œ 10ë…„ ì´ìƒ ì¤‘ì—ì„œ ê°€ì¥ í° ë³€í™”ì…ë‹ˆë‹¤. ì¤‘ì¦ ëŒ€ë™ë§¥ íŒë§‰ í˜‘ì°©ì¦(severe aortic stenosis)ì— ëŒ€í•´ ì‹ ì¤‘í•œ ê´€ì°°ì—ì„œ ì§ˆë³‘ ê²½ë¡œ ì´ˆê¸° ë‹¨ê³„ì—ì„œì˜ ì˜ë„ì ì´ê³  ê¸´ê¸‰í•œ ì¹˜ë£Œë¡œì˜ ì „í™˜ì´ë¼ëŠ” ì ì—ì„œ ì •ë§ ì¤‘ìš”í•œ ë³€í™”ì…ë‹ˆë‹¤. ì´ëŠ” ìƒë‹¹í•œ ë³€í™”ì´ë©°, íŠ¹íˆ ì˜ë¢° ë‹¨ê³„ì—ì„œ ë³€í™” ê´€ë¦¬ì™€ í–‰ë™ ë³€í™”ê°€ í•„ìš”í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ì´ëŸ¬í•œ ê°€ì´ë“œë¼ì¸ ë³€ê²½ì˜ ì±„íƒ ê³¡ì„ ì„ ê°€ì†í™”í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ ìœ„í•´ ìœ ëŸ½ì—ì„œ ì—¬ëŸ¬ ì¤‘ìš”í•œ í™•ëŒ€ í”„ë¡œê·¸ë¨ë“¤ì„ ì‹œì‘í–ˆê³  í˜„ì¬ ì‹¤í–‰ ì¤‘ì…ë‹ˆë‹¤. ì´ê²ƒì´ ì²« ë²ˆì§¸ í° ì‚¬í•­ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œëŠ” Scottê³¼ Bernardê°€ ì–¸ê¸‰í•œ AHA(ë¯¸êµ­ì‹¬ì¥í˜‘íšŒ)ì™€ì˜ íŒŒíŠ¸ë„ˆì‹­ì…ë‹ˆë‹¤. ì´ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•œ ì‚¬ì•ˆì´ë©°, ë‹¤ë…„ê°„ì˜ íŒŒíŠ¸ë„ˆì‹­ì…ë‹ˆë‹¤. ì´ íŒŒíŠ¸ë„ˆì‹­ì˜ ëª©ì ë„ ë™ì¼í•©ë‹ˆë‹¤. ëŒ€ë™ë§¥ í˜‘ì°©ì¦ì˜ ì§ˆë³‘ ê²½ë¡œì—ì„œ ì¡°ê¸° ì¹˜ë£Œì˜ ì¤‘ìš”ì„±ì— ëŒ€í•œ ëŒ€ì¤‘í™”ì™€ êµìœ¡ì…ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì€ ê°€ì´ë“œë¼ì¸ ê¸°ë°˜ ì¹˜ë£Œì™€ í™•ì¥ëœ ë°ì´í„° ìˆ˜ì§‘ì„ í†µí•´ ì¤‘ì¦ ëŒ€ë™ë§¥ í˜‘ì°©ì¦ì˜ ì§„ë‹¨ê³¼ ì¹˜ë£Œë¥¼ ê°œì„ í•˜ê¸° ìœ„í•´ ì„¤ê³„ë˜ì—ˆìœ¼ë©°, íŠ¹íˆ êµìœ¡ì— ì¤‘ì ì„ ë‘ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë‘ ê°€ì§€ê°€ í° íˆ¬ì í•­ëª©ì…ë‹ˆë‹¤. <br><br>ë˜í•œ ë¯¸êµ­ ë‚´ ì¹˜ë£Œìœ¨ í–¥ìƒê³¼ í™˜ì ë° ì˜ë¢° êµìœ¡ì„ ìœ„í•œ ë‹¨ê¸° íŒŒì¼ëŸ¿ ë‹¨ê³„ì˜ ë§ˆì¼€íŒ… í”„ë¡œê·¸ë¨ë“¤ì—ë„ ì¶”ê°€ íˆ¬ìë¥¼ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ìŠ¤ì½§ì´ ë§í–ˆë“¯ì´, í˜„ì¥ ì¸ë ¥ê³¼ ê´€ë ¨ëœ ë¶€ë¶„ë„ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³ ì ‘ì´‰ ë°©ì‹ì˜ í˜„ì¥ ì„ìƒ ì¸ë ¥ì„ ìš´ì˜í•˜ê³  ìˆìœ¼ë©°, ì‹œìˆ  ê±´ìˆ˜ê°€ ì¦ê°€í•˜ê³  ìˆê¸° ë•Œë¬¸ì— í˜„ì¥ ìì›ì„ ì„ ì œì ìœ¼ë¡œ í™•ë³´í•´ì•¼ í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì¸ë ¥ í™•ë³´ì—ëŠ” ì‹œê°„ì´ í•„ìš”í•©ë‹ˆë‹¤. êµìœ¡ê³¼ ìê²© ì¸ì¦ì— ì‹œê°„ì´ ê±¸ë¦½ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ê°€ ì¡°ê¸ˆ ì•ì„œì„œ ì¤€ë¹„í–ˆì§€ë§Œ, ì—°ì´ˆì— ìƒë‹¹ ë¶€ë¶„ ë’¤ì²˜ì¡Œë˜ ê²ƒë“¤ì´ 4ë¶„ê¸°ì— ë§ì´ ë”°ë¼ì¡í˜”ìŠµë‹ˆë‹¤. ì´ê²ƒë“¤ì´ ì£¼ìš” í•­ëª©ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And your next question comes from Travis Steed with Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ì˜ íŠ¸ë˜ë¹„ìŠ¤ ìŠ¤í‹°ë“œë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Travis Steed: BofA Securities, Research Division Congrats. Just wanted to maybe focus on for TAVR and total company growth. Anything to kind of call out for cadence over the year? And I wasn't clear on an organic basis, what Q1 was to me since I didn't have the FX impact in Q1? And any comments on kind of like the January trends that you've seen so far to give you confidence in the guide? Then I have a follow-up.</td><td>**Travis Steed:** TAVRì™€ ì „ì‚¬ ì„±ì¥ì— ëŒ€í•´ ì§‘ì¤‘í•´ì„œ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ì—°ì¤‘ ì„±ì¥ ì¶”ì´ì— ëŒ€í•´ íŠ¹ë³„íˆ ì–¸ê¸‰í•˜ì‹¤ ì‚¬í•­ì´ ìˆìœ¼ì‹ ê°€ìš”? ê·¸ë¦¬ê³  1ë¶„ê¸° ì‹¤ì ì´ ìœ ê¸°ì  ê¸°ì¤€ìœ¼ë¡œ ì •í™•íˆ ì–´ëŠ ì •ë„ì˜€ëŠ”ì§€ ëª…í™•í•˜ì§€ ì•Šì•˜ëŠ”ë°, 1ë¶„ê¸° í™˜ìœ¨ ì˜í–¥ì„ íŒŒì•…í•˜ì§€ ëª»í–ˆê±°ë“ ìš”. ê·¸ë¦¬ê³  ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ í™•ì‹ ì„ ì£¼ëŠ” 1ì›” íŠ¸ë Œë“œì— ëŒ€í•´ì„œë„ ì½”ë©˜íŠ¸ ë¶€íƒë“œë¦½ë‹ˆë‹¤. ì¶”ê°€ ì§ˆë¬¸ì´ í•˜ë‚˜ ë” ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Ullem: Corporate VP & CFO Thanks, Travis. Yes. So I mentioned that we expect about $40 million of tailwind from FX to sales. This has changed since our investor conference. A lot of that falls in the first quarter. And so we're expecting Q1 sales growth on a reported basis to be about 300 basis points higher than the underlying growth that we are expecting in Q1. Now remember, the first half growth rates in 2026 should be higher than the second half growth rates. And maybe Dan I will ask you to talk a little bit more about that.</td><td>**Scott Ullem:** ê°ì‚¬í•©ë‹ˆë‹¤, Travis. ë„¤, ë§ì”€ë“œë¦° ëŒ€ë¡œ ì™¸í™˜(FX)ìœ¼ë¡œ ì¸í•œ ë§¤ì¶œ ìˆœí’íš¨ê³¼ê°€ ì•½ 4ì²œë§Œ ë‹¬ëŸ¬ ì •ë„ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” íˆ¬ìì ì»¨í¼ëŸ°ìŠ¤ ì´í›„ ë³€ê²½ëœ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ ì¤‘ ìƒë‹¹ ë¶€ë¶„ì´ 1ë¶„ê¸°ì— ì§‘ì¤‘ë  ì˜ˆì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ 1ë¶„ê¸° ë³´ê³  ê¸°ì¤€ ë§¤ì¶œ ì„±ì¥ë¥ ì€ ìš°ë¦¬ê°€ ì˜ˆìƒí•˜ëŠ” ì‹¤ì§ˆ ì„±ì¥ë¥ ë³´ë‹¤ ì•½ 300bp ë†’ì„ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ 2026ë…„ ìƒë°˜ê¸° ì„±ì¥ë¥ ì´ í•˜ë°˜ê¸° ì„±ì¥ë¥ ë³´ë‹¤ ë†’ì„ ê²ƒì´ë¼ëŠ” ì ì„ ê¸°ì–µí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. Dan, ì´ ë¶€ë¶„ì— ëŒ€í•´ ì¢€ ë” ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Yes. Thanks, Scott. Travis, yes, it's true. The growth rate in our guidance moves down a little bit over the course of this year. As previously, we guided that the front half will be stronger than the back half in '26, and this is because we have much tougher, much higher year-over-year comps in the second half. We also applied classical seasonality and other assumptions to the year that weren't the case in 2025. That makes it a little bit more of a challenge. But the Q4 results that we had in 2025 give us increased confidence in our 6% to 8% guidance, and this is really important. On top of that, we have these meaningful tailwinds and catalysts later in the year that give us confidence in the mid- to-high single digit beyond 2026.</td><td>**Daniel Lippis:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Scott. Travis, ë§ìŠµë‹ˆë‹¤. ì˜¬í•´ ê°€ì´ë˜ìŠ¤ì˜ ì„±ì¥ë¥ ì´ ë‹¤ì†Œ ë‚®ì•„ì§€ëŠ” ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ì´ì „ì— ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ 26ë…„ë„ ìƒë°˜ê¸°ê°€ í•˜ë°˜ê¸°ë³´ë‹¤ ë” ê°•í•  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆëŠ”ë°, ì´ëŠ” í•˜ë°˜ê¸°ì— ì „ë…„ ëŒ€ë¹„ ë¹„êµ ê¸°ì¤€ì´ í›¨ì”¬ ë†’ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë˜í•œ 2025ë…„ì—ëŠ” ì ìš©ë˜ì§€ ì•Šì•˜ë˜ ì „í˜•ì ì¸ ê³„ì ˆì„±ê³¼ ê¸°íƒ€ ê°€ì •ë“¤ì„ ì˜¬í•´ì—ëŠ” ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì¸ë“¤ì´ ë‹¤ì†Œ ì–´ë ¤ì›€ì„ ê°€ì¤‘ì‹œí‚¤ëŠ” ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ 2025ë…„ 4ë¶„ê¸° ì‹¤ì ì´ 6%ì—ì„œ 8% ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ í™•ì‹ ì„ ë†’ì—¬ì£¼ì—ˆê³ , ì´ê²ƒì´ ì •ë§ ì¤‘ìš”í•œ ë¶€ë¶„ì…ë‹ˆë‹¤. <response><br><br>ì´ì— ë”í•´, ì—°ì¤‘ í›„ë°˜ì— ì˜ë¯¸ ìˆëŠ” ìˆœí’ê³¼ ì´‰ë§¤ì œë“¤ì´ ìˆì–´ 2026ë…„ ì´í›„ ì¤‘ìƒìœ„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì— ëŒ€í•œ í™•ì‹ ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Travis Steed: BofA Securities, Research Division Got it. And then I have a follow-up on the TAVR NCD. You called it a potential tailwind later this year. Just wanted to kind of think about how you're seeing that help growth more centers, faster patient pathways and if you read the public comments, they're all mostly positive on expanding the indication, but there's a bit more debate on the care team. So curious if you think how that shapes up in the final and how that might impact the different scenarios you're thinking about?</td><td>**Travis Steed:** ì•Œê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  TAVR NCD ê´€ë ¨í•´ì„œ ì¶”ê°€ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ ì ì¬ì  ìˆœí’ ìš”ì¸ì´ ë  ê²ƒì´ë¼ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ì´ê²ƒì´ ì–´ë–»ê²Œ ì„±ì¥ì— ë„ì›€ì´ ë ì§€ ìƒê°í•´ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ë” ë§ì€ ì„¼í„°, ë” ë¹ ë¥¸ í™˜ì ê²½ë¡œë¥¼ ì˜ë¯¸í•˜ëŠ” ê±´ì§€ìš”. ê·¸ë¦¬ê³  ê³µê°œ ì˜ê²¬ë“¤ì„ ë³´ë©´ ì ì‘ì¦ í™•ëŒ€ì— ëŒ€í•´ì„œëŠ” ëŒ€ë¶€ë¶„ ê¸ì •ì ì´ì§€ë§Œ, ì¹˜ë£ŒíŒ€ êµ¬ì„±ì— ëŒ€í•´ì„œëŠ” ë‹¤ì†Œ ë…¼ìŸì´ ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ìµœì¢…ì•ˆì—ì„œ ì´ ë¶€ë¶„ì´ ì–´ë–»ê²Œ ì •ë¦¬ë  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  ê·¸ê²ƒì´ ê·€ì‚¬ê°€ ìƒê°í•˜ê³  ê³„ì‹  ì—¬ëŸ¬ ì‹œë‚˜ë¦¬ì˜¤ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆì„ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Yes. So I'll take this one. I think, obviously, it's very, very important. The first phase -- first of all, it's important that the process was formally reopened. That was really important that happened right before the end of the year. And the first phase is now over, as Bernard mentioned. So we expect the initial draft around the June time frame. There will be a second round of public commentary at that point. And then assuming that the normal CMS process follows, the final determination could be in the Q4 time frame. So if you think about impact for 2026, negligible, but probably important and more relevant in 2027 and beyond. Now the key priority areas for us is to ensure timely and equitable access to care for patients, right? And the big win for patients would be coverage to label and any changes that may reduce procedural complexity or help improve equitable access to care. So that's what we're focused on. But we need to see what the draft looks like, and we look forward to the process continuing. And like you mentioned, we're also pleased that most of the commentary was positive and largely in line with our thinking.</td><td>**Daniel Lippis:** ë„¤, ì œê°€ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ ê³¼ì •ì´ ê³µì‹ì ìœ¼ë¡œ ì¬ê°œëœ ê²ƒì´ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. ì—°ë§ ì§ì „ì— ì´ë£¨ì–´ì§„ ê²ƒì´ ì •ë§ ì¤‘ìš”í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë²„ë‚˜ë“œê°€ ì–¸ê¸‰í–ˆë“¯ì´ 1ì°¨ ë‹¨ê³„ê°€ ì´ì œ ì¢…ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 6ì›” ê²½ì— ì´ˆì•ˆì´ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ì‹œì ì— 2ì°¨ ê³µê°œ ì˜ê²¬ ìˆ˜ë ´ì´ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì •ìƒì ì¸ CMS í”„ë¡œì„¸ìŠ¤ê°€ ì§„í–‰ëœë‹¤ê³  ê°€ì •í•˜ë©´, ìµœì¢… ê²°ì •ì€ 4ë¶„ê¸° ê²½ì— ë‚˜ì˜¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. 2026ë…„ ì˜í–¥ì„ ìƒê°í•´ë³´ë©´ ë¯¸ë¯¸í•œ ìˆ˜ì¤€ì´ì§€ë§Œ, 2027ë…„ê³¼ ê·¸ ì´í›„ì—ëŠ” ì¤‘ìš”í•˜ê³  ë” ì˜ë¯¸ìˆëŠ” ì˜í–¥ì´ ìˆì„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. í˜„ì¬ ì €í¬ì˜ í•µì‹¬ ìš°ì„ ìˆœìœ„ëŠ” í™˜ìë“¤ì´ ì ì‹œì— ê³µí‰í•˜ê²Œ ì¹˜ë£Œë¥¼ ë°›ì„ ìˆ˜ ìˆë„ë¡ ë³´ì¥í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. í™˜ìë“¤ì—ê²Œ ê°€ì¥ í° ì„±ê³¼ëŠ” ë¼ë²¨ ë²”ìœ„ ë‚´ ë³´í—˜ ì ìš©ê³¼ ì ˆì°¨ì  ë³µì¡ì„±ì„ ì¤„ì´ê±°ë‚˜ ì¹˜ë£Œ ì ‘ê·¼ì„± í˜•í‰ì„±ì„ ê°œì„ í•˜ëŠ” ë° ë„ì›€ì´ ë˜ëŠ” ë³€í™”ë“¤ì´ ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ê²ƒì´ ë°”ë¡œ ì €í¬ê°€ ì§‘ì¤‘í•˜ê³  ìˆëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ë‹¤ë§Œ ì´ˆì•ˆì´ ì–´ë–»ê²Œ ë‚˜ì˜¬ì§€ ì§€ì¼œë´ì•¼ í•˜ë©°, ì´ ê³¼ì •ì´ ê³„ì† ì§„í–‰ë˜ê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼, ëŒ€ë¶€ë¶„ì˜ ì˜ê²¬ì´ ê¸ì •ì ì´ì—ˆê³  ì €í¬ ìƒê°ê³¼ ëŒ€ì²´ë¡œ ì¼ì¹˜í–ˆë‹¤ëŠ” ì ë„ ê³ ë¬´ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from Larry Biegelsen with Wells Fargo.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Wells Fargoì˜ Larry Biegelsenë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Larry Biegelsen: Wells Fargo Securities, LLC, Research Division Yes. Two for me. I wanted to just ask about the LAA opportunity. How big is that market today? There's a competitor that has a device which sales of, I think, over $200 million. How is yours differentiated? And how do you want us to think about your LAA sales ramp over the next few years? And I had a follow-up.</td><td>**Larry Biegelsen:** ë„¤, ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. LAA ê¸°íšŒì— ëŒ€í•´ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. í˜„ì¬ ê·¸ ì‹œì¥ ê·œëª¨ëŠ” ì–´ëŠ ì •ë„ì…ë‹ˆê¹Œ? ê²½ìŸì‚¬ ì¤‘ í•œ ê³³ì´ 2ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ë§¤ì¶œì„ ì˜¬ë¦¬ê³  ìˆëŠ” ì œí’ˆì„ ë³´ìœ í•˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·€ì‚¬ì˜ ì œí’ˆì€ ì–´ë–¤ ì°¨ë³„ì ì´ ìˆìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  í–¥í›„ ëª‡ ë…„ê°„ LAA ë§¤ì¶œ ì¦ê°€ ì¶”ì´ë¥¼ ì–´ë–»ê²Œ ì „ë§í•´ì•¼ í• ê¹Œìš”? ì¶”ê°€ ì§ˆë¬¸ë„ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Thanks, Larry. We apply always the same filter. When we decide to get into a new space, it is all about is there a big unmet patient needs? Can we have an impact? Can we bring differentiated technologies? And so we look at this one and we say, yes, yes and yes. So how big it is? We don't know where very well in this segment yet, but we believe there is some technology out there. We believe there is still an unmet patient needs. And long term, we believe we can have an impact here. But I'm going to ask Daveen, which is very close to this one, to add some comments.</td><td>**CEO & Director:** ê°ì‚¬í•©ë‹ˆë‹¤, Larry. ì €í¬ëŠ” í•­ìƒ ë™ì¼í•œ ê¸°ì¤€ì„ ì ìš©í•©ë‹ˆë‹¤. ìƒˆë¡œìš´ ì˜ì—­ì— ì§„ì¶œí•˜ê¸°ë¡œ ê²°ì •í•  ë•ŒëŠ” ì¶©ì¡±ë˜ì§€ ì•Šì€ í° í™˜ì ë‹ˆì¦ˆê°€ ìˆëŠ”ì§€, ìš°ë¦¬ê°€ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆëŠ”ì§€, ì°¨ë³„í™”ëœ ê¸°ìˆ ì„ ì œê³µí•  ìˆ˜ ìˆëŠ”ì§€ë¥¼ ì‚´í´ë´…ë‹ˆë‹¤. ì´ ë¶„ì•¼ë¥¼ ê²€í† í–ˆì„ ë•Œ ì„¸ ê°€ì§€ ì§ˆë¬¸ ëª¨ë‘ì— ëŒ€í•œ ë‹µì´ 'ì˜ˆ'ì˜€ìŠµë‹ˆë‹¤. ì‹œì¥ ê·œëª¨ê°€ ì–¼ë§ˆë‚˜ ë˜ëŠ”ì§€ëŠ” ì•„ì§ ì´ ë¶„ì•¼ì— ëŒ€í•´ ì˜ ì•Œì§€ ëª»í•˜ì§€ë§Œ, ìœ ë§í•œ ê¸°ìˆ ë“¤ì´ ìˆë‹¤ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ì „íˆ ì¶©ì¡±ë˜ì§€ ì•Šì€ í™˜ì ë‹ˆì¦ˆê°€ ì¡´ì¬í•˜ë©°, ì¥ê¸°ì ìœ¼ë¡œ ìš°ë¦¬ê°€ ì´ ë¶„ì•¼ì—ì„œ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ì´ ê±´ì— ëŒ€í•´ ê¹Šì´ ê´€ì—¬í•˜ê³  ìˆëŠ” Daveenì—ê²Œ ì¶”ê°€ ì˜ê²¬ì„ ë¶€íƒë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daveen Chopra: Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Thanks, Bernard. Thanks, Larry, for the question. Yes. Obviously, as we mentioned, we're looking to enter the market later this year. And if you look at existing technologies out there, we think there's still unmet patient needs. And that's where we believe, obviously, that we can come out with the technology in this new therapeutic area for Edwards Surgical, we can come out with a solution that can really help patient care. And we see this as a complementary solution to our specific valvular procedures that we're already in. So as a result of that, we kind of see kind of a measured commercial rollout and opportunity to be a growth driver in the future for Edwards Surgical.</td><td>**Daveen Chopra:** ê°ì‚¬í•©ë‹ˆë‹¤, Bernard. Larry, ì§ˆë¬¸ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì˜¬í•´ í›„ë°˜ì— ì‹œì¥ ì§„ì…ì„ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œì¥ì— ë‚˜ì™€ ìˆëŠ” ê¸°ìˆ ë“¤ì„ ë³´ë©´, ì—¬ì „íˆ ì¶©ì¡±ë˜ì§€ ì•Šì€ í™˜ì ë‹ˆì¦ˆê°€ ì¡´ì¬í•œë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°”ë¡œ ì´ ë¶€ë¶„ì—ì„œ ì €í¬ê°€ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. Edwards Surgicalì˜ ìƒˆë¡œìš´ ì¹˜ë£Œ ì˜ì—­ì—ì„œ í™˜ì ì¹˜ë£Œì— ì‹¤ì§ˆì ì¸ ë„ì›€ì´ ë  ìˆ˜ ìˆëŠ” ì†”ë£¨ì…˜ì„ ì œê³µí•  ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. ì´ëŠ” ì €í¬ê°€ ì´ë¯¸ ì§„í–‰í•˜ê³  ìˆëŠ” íŠ¹ì • íŒë§‰ ì‹œìˆ ë“¤ê³¼ ìƒí˜¸ë³´ì™„ì ì¸ ì†”ë£¨ì…˜ì´ ë  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë‹¨ê³„ì ì¸ ìƒì—…ì  ì¶œì‹œë¥¼ ì§„í–‰í•˜ë©´ì„œ, í–¥í›„ Edwards Surgicalì˜ ì„±ì¥ ë™ë ¥ì´ ë  ìˆ˜ ìˆëŠ” ê¸°íšŒë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Larry Biegelsen: Wells Fargo Securities, LLC, Research Division That's super helpful. Bernard, we saw a long list of catalysts in '26 in your press release today. And I think people will notice that you didn't mention moderate AS. So can you talk about why you left that out? And how you're thinking about the moderate opportunity today?</td><td>**Larry Biegelsen:** ì •ë§ ë„ì›€ì´ ë˜ëŠ” ë‹µë³€ì´ì—ˆìŠµë‹ˆë‹¤. ë²„ë‚˜ë“œ, ì˜¤ëŠ˜ ë³´ë„ìë£Œì—ì„œ 2026ë…„ ì—¬ëŸ¬ ì´‰ë§¤ì œ ëª©ë¡ì„ ë´¤ëŠ”ë°ìš”. ì¤‘ë“±ë„ ëŒ€ë™ë§¥íŒë§‰í˜‘ì°©ì¦(moderate AS)ì€ ì–¸ê¸‰í•˜ì§€ ì•Šìœ¼ì‹  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì™œ ë¹ ëœ¨ë¦¬ì…¨ëŠ”ì§€, ê·¸ë¦¬ê³  í˜„ì¬ ì¤‘ë“±ë„ í™˜ìêµ° ê¸°íšŒë¥¼ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>CEO & Director: Thanks, Larry. I'm glad you saw a long list and indeed, it is a very long list. And let me first talk a little bit about why all of these catalysts that we get to your question about moderate. The risk is very long because of our very unique strategy, where we invest early, we are very committed. We have a flawless execution. I'm sure you have seen that the kind of results we have had in 2025 is pretty spectacular. Financially, having all these catalysts, new technologies, new evidence, lasting evidence, lasting impact. All of them are basically in play for this year. With moderate, for sure, moderate is a big category. We know that the moderate prevalence is bigger than the severe one. We know it is big, but at the same time, we don't know what the study result will be. So we are waiting to know more about PROGRESS, the PROGRESS trial, which will be presented at TCT to talk more about it. But at least what you have seen is where we know for sure when it is coming and the type of impact we are going to have. Progress and moderate, big opportunity, we don't know yet we have the study results.</td><td>**CEO & Director:** ê°ì‚¬í•©ë‹ˆë‹¤, Larry. ê¸´ ëª©ë¡ì„ ë³´ì…¨ë‹¤ë‹ˆ ê¸°ì©ë‹ˆë‹¤. ì‹¤ì œë¡œ ë§¤ìš° ê¸´ ëª©ë¡ì´ ë§ìŠµë‹ˆë‹¤. ë¨¼ì € ì´ ëª¨ë“  ì„±ì¥ ì´‰ë§¤ì œë“¤ì— ëŒ€í•´, ê·¸ë¦¬ê³  ì¤‘ë“±ë„(moderate)ì— ëŒ€í•œ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê¸° ì „ì— ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ë ‡ê²Œ ëª©ë¡ì´ ê¸´ ì´ìœ ëŠ” ìš°ë¦¬ì˜ ë§¤ìš° ë…íŠ¹í•œ ì „ëµ ë•Œë¬¸ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì¡°ê¸°ì— íˆ¬ìí•˜ê³ , ë§¤ìš° í—Œì‹ ì ì´ë©°, ì™„ë²½í•œ ì‹¤í–‰ë ¥ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì— ìš°ë¦¬ê°€ ê±°ë‘” ì„±ê³¼ê°€ ìƒë‹¹íˆ ë†€ë¼ì› ë‹¤ëŠ” ê²ƒì„ ë³´ì…¨ì„ ê²ë‹ˆë‹¤. ì¬ë¬´ì ìœ¼ë¡œ, ì´ ëª¨ë“  ì´‰ë§¤ì œë“¤ - ì‹ ê¸°ìˆ , ìƒˆë¡œìš´ ì„ìƒ ê·¼ê±°, ì§€ì†ì ì¸ ê·¼ê±°, ì§€ì†ì ì¸ ì˜í–¥ë ¥ - ì´ ëª¨ë“  ê²ƒë“¤ì´ ê¸°ë³¸ì ìœ¼ë¡œ ì˜¬í•´ ì‘ë™í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì¤‘ë“±ë„ì˜ ê²½ìš°, í™•ì‹¤íˆ ì¤‘ë“±ë„ëŠ” í° ì¹´í…Œê³ ë¦¬ì…ë‹ˆë‹¤. ì¤‘ë“±ë„ ìœ ë³‘ë¥ ì´ ì¤‘ì¦ë³´ë‹¤ í¬ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì‹œì¥ì´ í¬ë‹¤ëŠ” ê²ƒì€ ì•Œì§€ë§Œ, ë™ì‹œì— ì„ìƒì‹œí—˜ ê²°ê³¼ê°€ ì–´ë–»ê²Œ ë‚˜ì˜¬ì§€ëŠ” ì•„ì§ ëª¨ë¦…ë‹ˆë‹¤. ì €í¬ëŠ” PROGRESS ì„ìƒì‹œí—˜ì— ëŒ€í•´ ë” ìì„¸íˆ ì•Œê¸° ìœ„í•´ ê¸°ë‹¤ë¦¬ê³  ìˆìœ¼ë©°, ì´ëŠ” TCTì—ì„œ ë°œí‘œë  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë•Œ ë” ìì„¸íˆ ë§ì”€ë“œë¦´ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì ì–´ë„ ì—¬ëŸ¬ë¶„ê»˜ì„œ ë³´ì‹  ê²ƒì€ ì €í¬ê°€ í™•ì‹¤íˆ ì•Œê³  ìˆëŠ” ë¶€ë¶„, ì¦‰ ì–¸ì œ ì¶œì‹œë˜ëŠ”ì§€ì™€ ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì¸ì§€ì— ëŒ€í•œ ê²ƒì…ë‹ˆë‹¤. <br><br>PROGRESSì™€ ì¤‘ë“±ë„ ë³‘ë³€ì€ í° ê¸°íšŒì…ë‹ˆë‹¤ë§Œ, ì•„ì§ ì„ìƒ ê²°ê³¼ë¥¼ í™•ë³´í•˜ì§€ ëª»í–ˆê¸° ë•Œë¬¸ì— í™•ì‹¤í•˜ê²Œ ë§ì”€ë“œë¦´ ìˆ˜ ì—†ëŠ” ìƒí™©ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from David Roman with Goldman Sachs.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ë‹¤ìŒ ì§ˆë¬¸ì€ Goldman Sachsì˜ David Romanë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Roman: Goldman Sachs Group, Inc., Research Division I was hoping you could go into a little bit more detail on the comments regarding lifetime management for TAVR. And maybe more specifically talk about what you think the implications will be to valve and vendor selection, balloon expandable versus self-expandable? How that might end up being a contributor to incremental market share gains as you think about the TAVR business here in 2026 and beyond.</td><td>**David Roman:** TAVRì˜ í‰ìƒ ê´€ë¦¬(lifetime management)ì— ëŒ€í•œ ì–¸ê¸‰ê³¼ ê´€ë ¨í•´ì„œ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? íŠ¹íˆ íŒë§‰ ë° ê³µê¸‰ì—…ì²´ ì„ íƒ, í’ì„  í™•ì¥í˜•(balloon expandable) ëŒ€ ìê°€ í™•ì¥í˜•(self-expandable) íŒë§‰ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹ ì§€ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤. 2026ë…„ ì´í›„ TAVR ì‚¬ì—…ì˜ ì ì§„ì ì¸ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ì— ì´ê²ƒì´ ì–´ë–»ê²Œ ê¸°ì—¬í•  ìˆ˜ ìˆì„ì§€ì— ëŒ€í•œ ê²¬í•´ë„ ë¶€íƒë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: I know that. Dan has a lot of passion about this one. So I'm going to let Dan talk about this.</td><td>**CEO & Director:** ì•Œê² ìŠµë‹ˆë‹¤. Danì´ ì´ ë¶€ë¶„ì— ëŒ€í•´ ì—´ì •ì´ ë§ê±°ë“ ìš”. ê·¸ë˜ì„œ Danì—ê²Œ ë§ì”€ë“œë¦¬ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) You're on the right point, David. I mean, look, the evidence -- and when I say evidence, I'm talking the EARLY TAVR evidence, the sub-analyses from EARLY TAVR, the evidence that the likes of Philippe Genereux has published now on acute bowel syndrome. And then you've got PARTNER III and PARTNER II long-term data on top of this, all pointing to the fact that you're going to get a better clinical and economic benefit if you treat earlier in the disease pathway. This is a huge shift, and it changes the conversation between doctor and patient. So if you can imagine a year ago or a little bit more, you might have -- it might have been something along the lines of, let's see if we can eat this out another 6 months or 12 months or maybe a patient would want to thinking that they're trying to time their treatment and trying to figure out how to make their valve last as long as possible to avoid secondary or tertiary procedures. And this conversation has completely shifted because the evidence says that the benefit of doing that is not -- there's no upside to that, right? There's no upside to waiting anymore. And so this brings into the very important conversation and the concept of lifetime management. This is very, very important because you got to get the first procedure right to make sure you've got options and the right options for patients for their second procedure, whether that be another valve and valve or whether that be coronary artery access, PCI or what have you. And so we think our platform is uniquely positioned both acutely and with lifetime management options, whether that be secondary or tertiary procedures. And I think that's going to be one of the key value propositions that we have not only immediately but in the years to come.</td><td>**Daniel Lippis:** ë§ìŠµë‹ˆë‹¤, David. ì¦ê±°ë“¤ì„ ë³´ë©´ - ì—¬ê¸°ì„œ ì¦ê±°ë¼ê³  í•˜ë©´ EARLY TAVR ì—°êµ¬ ê²°ê³¼, EARLY TAVRì˜ í•˜ìœ„ ë¶„ì„ë“¤, Philippe Genereuxê°€ ë°œí‘œí•œ ê¸‰ì„± ì¥ ì¦í›„êµ°(acute bowel syndrome)ì— ê´€í•œ ì—°êµ¬ë¥¼ ë§í•˜ëŠ” ê²ë‹ˆë‹¤. ê·¸ë¦¬ê³  PARTNER IIIì™€ PARTNER IIì˜ ì¥ê¸° ë°ì´í„°ê¹Œì§€ ë”í•´ì§€ë©´ì„œ, ì´ ëª¨ë“  ê²ƒë“¤ì´ ì§ˆë³‘ ê²½ë¡œì˜ ì´ˆê¸° ë‹¨ê³„ì—ì„œ ì¹˜ë£Œí•  ë•Œ ë” ë‚˜ì€ ì„ìƒì , ê²½ì œì  ì´ì ì„ ì–»ì„ ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ì—„ì²­ë‚œ ë³€í™”ì´ë©°, ì˜ì‚¬ì™€ í™˜ì ê°„ì˜ ëŒ€í™” ë°©ì‹ ìì²´ë¥¼ ë°”ê¾¸ëŠ” ê²ƒì…ë‹ˆë‹¤. 1ë…„ ì „ì´ë‚˜ ê·¸ë³´ë‹¤ ì¡°ê¸ˆ ë” ì „ë§Œ í•´ë„ ìƒí™©ì„ ìƒìƒí•´ë³´ì‹œë©´, "6ê°œì›”ì´ë‚˜ 12ê°œì›” ì •ë„ ë” ë²„í…¨ë³¼ ìˆ˜ ìˆì§€ ì•Šì„ê¹Œ"ë¼ëŠ” ì‹ì˜ ëŒ€í™”ê°€ ì˜¤ê°”ì„ ê²ë‹ˆë‹¤. í™˜ìë“¤ë„ 2ì°¨, 3ì°¨ ì‹œìˆ ì„ í”¼í•˜ê¸° ìœ„í•´ íŒë§‰ì„ ìµœëŒ€í•œ ì˜¤ë˜ ìœ ì§€í•˜ë ¤ê³  ì¹˜ë£Œ ì‹œê¸°ë¥¼ ì¡°ìœ¨í•˜ë ¤ëŠ” ìƒê°ì„ í–ˆì—ˆì£ . ê·¸ëŸ°ë° ì´ëŸ° ëŒ€í™”ëŠ” ì™„ì „íˆ ë°”ë€Œì—ˆìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì„ìƒ ê·¼ê±°ë“¤ì´ ê·¸ë ‡ê²Œ í•˜ëŠ” ê²ƒì˜ ì´ì ì´ ì—†ë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì£¼ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë” ì´ìƒ ê¸°ë‹¤ë¦¬ëŠ” ê²ƒì— ëŒ€í•œ ì´ì ì´ ì „í˜€ ì—†ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ì œëŠ” ë§¤ìš° ì¤‘ìš”í•œ ëŒ€í™”, ì¦‰ í‰ìƒ ê´€ë¦¬(lifetime management)ë¼ëŠ” ê°œë…ìœ¼ë¡œ ë…¼ì˜ê°€ ì˜®ê²¨ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•œ ë¶€ë¶„ì…ë‹ˆë‹¤. ì²« ë²ˆì§¸ ì‹œìˆ ì„ ì œëŒ€ë¡œ í•´ì•¼ í™˜ìë“¤ì´ ë‘ ë²ˆì§¸ ì‹œìˆ ì„ ë°›ì„ ë•Œ ì ì ˆí•œ ì˜µì…˜ë“¤ì„ í™•ë³´í•  ìˆ˜ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ ì‹œìˆ ì´ ë˜ ë‹¤ë¥¸ íŒë§‰-ë‚´-íŒë§‰(valve-in-valve) ì‹œìˆ ì´ ë˜ë“ , ê´€ìƒë™ë§¥ ì ‘ê·¼ì´ë‚˜ ê²½í”¼ì  ê´€ìƒë™ë§¥ ì¤‘ì¬ìˆ (PCI) ë“±ì´ ë˜ë“  ë§ì´ì£ . ê·¸ë˜ì„œ ì €í¬ í”Œë«í¼ì€ ê¸‰ì„±ê¸° ì¹˜ë£Œë¿ë§Œ ì•„ë‹ˆë¼ í‰ìƒ ê´€ë¦¬ ì¸¡ë©´ì—ì„œë„ ë…ë³´ì ì¸ ìœ„ì¹˜ì— ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. 2ì°¨ ì‹œìˆ ì´ë“  3ì°¨ ì‹œìˆ ì´ë“  ëª¨ë“  ì˜µì…˜ì„ ì œê³µí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ë‹¹ì¥ì€ ë¬¼ë¡ ì´ê³  ì•ìœ¼ë¡œ ìˆ˜ë…„ê°„ ì €í¬ê°€ ê°€ì§„ í•µì‹¬ ê°€ì¹˜ ì œì•ˆ ì¤‘ í•˜ë‚˜ê°€ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>David Roman: Goldman Sachs Group, Inc., Research Division And maybe just a clarification there. So in that scenario, is it reasonable to expect that just a significant percentage of patients receiving TAVR either in the asymptomatic or call it the sub-75 population that creates a unique opportunity for SAPIEN? And maybe just my follow-up, I'd ask you on capital allocation. You've obviously pulled the JenaValve deal did not end up coming to fruition. You bought back a good amount of stock last year, but you've also made some key hires to the business development team. Maybe just talk to us about your latest thinking here on capital allocation.</td><td>**David Roman:** ê·¸ë¦¬ê³  ê·¸ ë¶€ë¶„ì— ëŒ€í•´ ëª…í™•íˆ í•˜ìë©´, ê·¸ëŸ° ì‹œë‚˜ë¦¬ì˜¤ì—ì„œ ë¬´ì¦ìƒ í™˜ìë‚˜ 75ì„¸ ë¯¸ë§Œ í™˜ìêµ°ì—ì„œ TAVRë¥¼ ë°›ëŠ” í™˜ìë“¤ì˜ ìƒë‹¹ ë¹„ìœ¨ì´ SAPIENì—ê²Œ ë…íŠ¹í•œ ê¸°íšŒë¥¼ ë§Œë“¤ì–´ë‚¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ” ê²Œ í•©ë¦¬ì ì¼ê¹Œìš”? ê·¸ë¦¬ê³  í›„ì† ì§ˆë¬¸ìœ¼ë¡œ ìë³¸ ë°°ë¶„ì— ëŒ€í•´ ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. JenaValve ì¸ìˆ˜ ê±´ì´ ì„±ì‚¬ë˜ì§€ ì•Šì•˜ê³ , ì‘ë…„ì— ìƒë‹¹í•œ ê·œëª¨ì˜ ìì‚¬ì£¼ ë§¤ì…ì„ í•˜ì…¨ëŠ”ë°, ë™ì‹œì— ì‚¬ì—…ê°œë°œíŒ€ì— í•µì‹¬ ì¸ë ¥ë“¤ë„ ì˜ì…í•˜ì…¨ìŠµë‹ˆë‹¤. ìë³¸ ë°°ë¶„ì— ëŒ€í•œ ìµœê·¼ ìƒê°ì„ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Yes. So as far as the -- look, whether it be younger patients or whether it be elderly patients, there's a good chance now with modern medicine and the way that this is going, that patients will outlive their first valve. I mean it's -- I think lifetime management considerations is not just now for youthful patients. And in fact, more and more, we see -- we find ourselves in scenarios where certain valve platforms were chosen with the idea that the patient would not outlive that valve and then finding the options for that patient limited at that time point, which is really disappointing. So this lifetime management thing, getting the first procedure right upfront is a big thing. It is a conversation that everybody is focused on in the clinical community. Now as far as strategic allocation, look, we think valve and valve and whether you throw in leaflet modification or other types of things associated with secondary procedures, we think this is going to be very real. It's small now, but it will be growing. It's all about the denominator, right, and the numerator. And so we're looking at ways, as we always do to lead in this space. And that's something that we're looking at very, very closely. The other thing that, obviously, we do is we look at how we apply our field force here and how we invest in our field force and what kind of value that we bring with our service model as these conversations and these types of procedures evolve in terms of how to get the best outcome for a patient at any given time.</td><td>**Daniel Lippis:** ë„¤, í˜„ëŒ€ ì˜í•™ì˜ ë°œì „ê³¼ ì¹˜ë£Œ ë°©í–¥ì„ ê³ ë ¤í•  ë•Œ, ì Šì€ í™˜ìë“  ê³ ë ¹ í™˜ìë“  ìƒê´€ì—†ì´ ì´ì œëŠ” í™˜ìë“¤ì´ ì²« ë²ˆì§¸ íŒë§‰ë³´ë‹¤ ë” ì˜¤ë˜ ìƒì¡´í•  ê°€ëŠ¥ì„±ì´ ìƒë‹¹íˆ ë†’ì•„ì¡ŒìŠµë‹ˆë‹¤. í‰ìƒ ê´€ë¦¬(lifetime management) ì¸¡ë©´ì˜ ê³ ë ¤ì‚¬í•­ì€ ë” ì´ìƒ ì Šì€ í™˜ìë“¤ë§Œì˜ ë¬¸ì œê°€ ì•„ë‹™ë‹ˆë‹¤. ì‹¤ì œë¡œ ì ì  ë” ë§ì€ ê²½ìš°ì—ì„œ, í™˜ìê°€ í•´ë‹¹ íŒë§‰ë³´ë‹¤ ì˜¤ë˜ ì‚´ì§€ ëª»í•  ê²ƒì´ë¼ëŠ” ì „ì œ í•˜ì— íŠ¹ì • íŒë§‰ í”Œë«í¼ì„ ì„ íƒí–ˆë‹¤ê°€, ë‚˜ì¤‘ì— ê·¸ í™˜ìì—ê²Œ ì„ íƒí•  ìˆ˜ ìˆëŠ” ì˜µì…˜ì´ ì œí•œë˜ëŠ” ìƒí™©ì„ ëª©ê²©í•˜ê²Œ ë˜ëŠ”ë°, ì´ëŠ” ì •ë§ ì•ˆíƒ€ê¹Œìš´ ì¼ì…ë‹ˆë‹¤. ë”°ë¼ì„œ í‰ìƒ ê´€ë¦¬ ê´€ì ì—ì„œ ì²˜ìŒ ì‹œìˆ ì„ ì œëŒ€ë¡œ í•˜ëŠ” ê²ƒì´ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. ì´ëŠ” ì„ìƒ ì»¤ë®¤ë‹ˆí‹°ì—ì„œ ëª¨ë‘ê°€ ì£¼ëª©í•˜ê³  ìˆëŠ” ëŒ€í™” ì£¼ì œì…ë‹ˆë‹¤. ì „ëµì  ìì› ë°°ë¶„ ì¸¡ë©´ì—ì„œ ë³´ë©´, íŒë§‰ ê´€ë ¨ ì‹œìˆ , ê·¸ë¦¬ê³  ì²¨íŒ ìˆ˜ì •ìˆ ì´ë‚˜ ì´ì°¨ ì‹œìˆ ê³¼ ê´€ë ¨ëœ ë‹¤ë¥¸ ìœ í˜•ì˜ ì‹œìˆ ë“¤ì„ í¬í•¨í•´ì„œ, ì´ê²ƒì´ ë§¤ìš° ì‹¤ì§ˆì ì¸ ì‹œì¥ì´ ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì§€ê¸ˆì€ ê·œëª¨ê°€ ì‘ì§€ë§Œ ì„±ì¥í•  ê²ƒì…ë‹ˆë‹¤. ê²°êµ­ ë¶„ëª¨ì™€ ë¶„ìì˜ ë¬¸ì œì´ì£ . ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” í•­ìƒ ê·¸ë˜ì™”ë“¯ì´ ì´ ë¶„ì•¼ì—ì„œ ì„ ë„ì  ìœ„ì¹˜ë¥¼ ì°¨ì§€í•  ìˆ˜ ìˆëŠ” ë°©ë²•ë“¤ì„ ëª¨ìƒ‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ë§¤ìš° ë©´ë°€íˆ ê²€í† í•˜ê³  ìˆëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ë˜í•œ ì €í¬ê°€ ì£¼ëª©í•˜ëŠ” ë¶€ë¶„ì€ í˜„ì¥ ì¸ë ¥ì„ ì–´ë–»ê²Œ ë°°ì¹˜í•˜ê³  íˆ¬ìí•  ê²ƒì¸ê°€, ê·¸ë¦¬ê³  í™˜ìì—ê²Œ ìµœìƒì˜ ì¹˜ë£Œ ê²°ê³¼ë¥¼ ì œê³µí•˜ê¸° ìœ„í•œ ë…¼ì˜ì™€ ì‹œìˆ  ë°©ì‹ì´ ë°œì „í•´ ë‚˜ê°€ëŠ” ê³¼ì •ì—ì„œ ì €í¬ ì„œë¹„ìŠ¤ ëª¨ë¸ì´ ì–´ë–¤ ê°€ì¹˜ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ”ê°€ í•˜ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Scott Ullem: Corporate VP & CFO And on capital allocation, David, our priorities have not changed. Our first priority is investing in the business to support our growth. And that comes in the form of making sure we've got sufficient production capacity. And as we mentioned at the investor conference, we are increasing our production capacity to keep up with the growth in TAVR, and TMTT and Surgical. It also involves making external investments. And so we've got a number of different activities underway. We've always been active in M&A. As you know, most of the things that we invest in or purchase tend to be smaller in size because we're focused on structural heart. But that's going to be a continual direction for allocation of capital. And then share repurchase is one of our best ways to return capital to shareholders. And we continued our share repurchase activities in the fourth quarter. We bought back about $40 million, bringing the total repurchase in 2025 to just under $900 million. We still have about $2 billion of authorization remaining. And you should expect that we're going to continue to look for opportunistic times to repurchase more shares.</td><td>**Scott Ullem:** ìë³¸ ë°°ë¶„ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ë°ì´ë¹„ë“œ, ì €í¬ì˜ ìš°ì„ ìˆœìœ„ëŠ” ë³€í•¨ì´ ì—†ìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ ìš°ì„ ìˆœìœ„ëŠ” ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•œ ì‚¬ì—… íˆ¬ìì…ë‹ˆë‹¤. ì´ëŠ” ì¶©ë¶„í•œ ìƒì‚° ëŠ¥ë ¥ì„ í™•ë³´í•˜ëŠ” í˜•íƒœë¡œ ì´ë£¨ì–´ì§‘ë‹ˆë‹¤. íˆ¬ìì ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì €í¬ëŠ” TAVR, TMTT, ê·¸ë¦¬ê³  ì™¸ê³¼ ë¶€ë¬¸ì˜ ì„±ì¥ì— ë°œë§ì¶”ê¸° ìœ„í•´ ìƒì‚° ëŠ¥ë ¥ì„ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì™¸ë¶€ íˆ¬ìë„ í¬í•¨ë©ë‹ˆë‹¤. í˜„ì¬ ì—¬ëŸ¬ ê°€ì§€ í™œë™ë“¤ì„ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ì €í¬ëŠ” í•­ìƒ M&Aì— ì ê·¹ì ì´ì—ˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ì €í¬ê°€ íˆ¬ìí•˜ê±°ë‚˜ ì¸ìˆ˜í•˜ëŠ” ëŒ€ë¶€ë¶„ì˜ ê±´ë“¤ì€ êµ¬ì¡°ì  ì‹¬ì¥ì§ˆí™˜(structural heart)ì— ì§‘ì¤‘í•˜ê³  ìˆê¸° ë•Œë¬¸ì— ê·œëª¨ê°€ ì‘ì€ í¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ê³„ì†í•´ì„œ ìë³¸ ë°°ë¶„ì˜ ë°©í–¥ì´ ë  ê²ƒì…ë‹ˆë‹¤. ìì‚¬ì£¼ ë§¤ì…ì€ ì£¼ì£¼ë“¤ì—ê²Œ ìë³¸ì„ í™˜ì›í•˜ëŠ” ê°€ì¥ ì¢‹ì€ ë°©ë²• ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. 4ë¶„ê¸°ì—ë„ ìì‚¬ì£¼ ë§¤ì…ì„ ì§€ì†í–ˆìŠµë‹ˆë‹¤. ì•½ 4ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ë§¤ì…í–ˆê³ , 2025ë…„ ì´ ë§¤ì… ê·œëª¨ëŠ” 9ì–µ ë‹¬ëŸ¬ì— ì¡°ê¸ˆ ëª» ë¯¸ì¹©ë‹ˆë‹¤. ì•„ì§ ì•½ 20ì–µ ë‹¬ëŸ¬ì˜ ìŠ¹ì¸ëœ í•œë„ê°€ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œë„ ì ì ˆí•œ ì‹œê¸°ë¥¼ í¬ì°©í•´ì„œ ìì‚¬ì£¼ ë§¤ì…ì„ ê³„ì† ì§„í–‰í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œë©´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And your next question comes from Joanne Wuensch with Citibank.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ë‹¤ìŒ ì§ˆë¬¸ì€ ì”¨í‹°ì€í–‰ì˜ ì¡°ì•¤ ìš°ì—”ì‰¬ ì• ë„ë¦¬ìŠ¤íŠ¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Joanne Wuensch: Citigroup Inc., Research Division Could you give us a little bit of the state of the union on how M3 is being taken up in the United States and any -- or what impacts are going outside the United States? And then if you could just sort of flesh out and give a little bit more color on the guideline changes that are happening in Europe and how to think about those impacts for the remainder of the year?</td><td>**Joanne Wuensch:** ë¯¸êµ­ì—ì„œ M3ì˜ ë„ì… í˜„í™©ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œì˜ ì˜í–¥ì€ ì–´ë–¤ì§€, ë˜í•œ ìœ ëŸ½ì—ì„œ ì§„í–‰ ì¤‘ì¸ ê°€ì´ë“œë¼ì¸ ë³€ê²½ ì‚¬í•­ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ì£¼ì‹œê³ , ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ ë™ì•ˆ ê·¸ ì˜í–¥ì„ ì–´ë–»ê²Œ ë´ì•¼ í• ì§€ ë§ì”€í•´ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Daveen Chopra: Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Thanks, Joanne, It's Daveen. I appreciate the question. Talk a little bit about the SAPIEN M3 launch. We're just starting in the U.S., right? We got approval, obviously, right before the end of the year. And it's kind of scaling in line with our expectations here in the U.S. and we are just starting to open up centers, really focusing on centers who are, in our who are in our ENCIRCLE pivotal clinical study first. In Europe, we're scaling in line with expectations as well, but it's still pretty early in the process. I think what we like that we're seeing is that we're getting really high procedural success, and we're getting really great patient outcomes. Remember I was with a patient just the other week who had previously had mitral valve surgery and then needed an M3 because the surgery had failed. And for him, hearing about the difference his life made when he had no other tear or surgical alternatives with mitral regurgitation really hurting his life and how it just got so much better, just it worn my heart so much to kind of hear that. So because of that, we're seeing this physician excitement because there's a group of patients who didn't -- who don't really have tear or have great surgical options for which M3 really becomes a good opportunity. So for us, we're continuing to appropriately kind of scale up, open up new centers and bring this therapy to new patients. So that's kind of SAPIEN M3. And maybe moving on to kind of European guidelines, you want to start with TAVR guidelines? The European guidelines, I can talk about the FMR guidelines a little bit. Yes. So on the European guidelines with FMR, they're now Class I for functional mitral regurgitation for reduction of heart failure hospitalizations. So we're seeing, I think, increased awareness, specifically in mitral and tricuspid, increased awareness for these 2 diseases and increased kind of referrals happening with this guideline shift. So we see it as a helping continue that double-digit tier market growth that we've been seeing. And maybe passing on to TAVR for a comment on the guidelines, Dan.</td><td>**Daveen Chopra:** ê°ì‚¬í•©ë‹ˆë‹¤, ì¡°ì•¤. ë‹¤ë¹ˆì…ë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. SAPIEN M3 ì¶œì‹œì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œëŠ” ì´ì œ ë§‰ ì‹œì‘í•˜ëŠ” ë‹¨ê³„ì…ë‹ˆë‹¤. ì—°ë§ ì§ì „ì— ìŠ¹ì¸ì„ ë°›ì•˜ê³ , í˜„ì¬ ë¯¸êµ­ì—ì„œ ìš°ë¦¬ ì˜ˆìƒì— ë§ì¶° í™•ëŒ€ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ê¸ˆì€ ì„¼í„°ë“¤ì„ ê°œì„¤í•˜ê¸° ì‹œì‘í•˜ëŠ” ë‹¨ê³„ì¸ë°, íŠ¹íˆ ìš°ë¦¬ ENCIRCLE ì¤‘ì‹¬ ì„ìƒì‹œí—˜ì— ì°¸ì—¬í–ˆë˜ ì„¼í„°ë“¤ì„ ìš°ì„ ì ìœ¼ë¡œ ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìœ ëŸ½ì—ì„œë„ ì˜ˆìƒëŒ€ë¡œ í™•ëŒ€ë˜ê³  ìˆì§€ë§Œ, ì•„ì§ì€ ì´ˆê¸° ë‹¨ê³„ì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆëŠ” ì ì€ ë§¤ìš° ë†’ì€ ì‹œìˆ  ì„±ê³µë¥ ì„ ë‹¬ì„±í•˜ê³  ìˆê³ , í™˜ì ê²°ê³¼ë„ ì •ë§ ìš°ìˆ˜í•˜ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë¶ˆê³¼ ì§€ë‚œì£¼ì—ë„ ìŠ¹ëª¨íŒë§‰ ìˆ˜ìˆ ì„ ë°›ì•˜ë‹¤ê°€ ìˆ˜ìˆ ì´ ì‹¤íŒ¨í•´ì„œ M3ê°€ í•„ìš”í–ˆë˜ í™˜ìë¥¼ ë§Œë‚¬ìŠµë‹ˆë‹¤. ìŠ¹ëª¨íŒ ì—­ë¥˜ì¦ìœ¼ë¡œ ì‚¶ì˜ ì§ˆì´ ë§ì´ ë–¨ì–´ì¡ŒëŠ”ë° ë‹¤ë¥¸ ê²½í”¼ì  ì‹œìˆ ì´ë‚˜ ìˆ˜ìˆ ì  ëŒ€ì•ˆì´ ì—†ë˜ ìƒí™©ì—ì„œ, M3 ì‹œìˆ  í›„ ì‚¶ì´ ì–¼ë§ˆë‚˜ ë‚˜ì•„ì¡ŒëŠ”ì§€ ë“£ëŠ” ìˆœê°„ ì •ë§ ê°€ìŠ´ì´ ë­‰í´í–ˆìŠµë‹ˆë‹¤. <br><br>ì´ëŸ° ê²½í—˜ ë•Œë¬¸ì— ì˜ì‚¬ë“¤ì˜ ê´€ì‹¬ì´ ë†’ì•„ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê²½í”¼ì  ì‹œìˆ ì´ ì–´ë µê±°ë‚˜ ì ì ˆí•œ ìˆ˜ìˆ  ì˜µì…˜ì´ ì—†ëŠ” í™˜ìêµ°ì—ê²Œ M3ê°€ ì •ë§ ì¢‹ì€ ê¸°íšŒê°€ ë˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ì ì ˆí•œ ì†ë„ë¡œ ê·œëª¨ë¥¼ í™•ëŒ€í•˜ê³ , ìƒˆë¡œìš´ ì„¼í„°ë“¤ì„ ê°œì„¤í•˜ë©´ì„œ ë” ë§ì€ í™˜ìë“¤ì—ê²Œ ì´ ì¹˜ë£Œë²•ì„ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. SAPIEN M3ì— ëŒ€í•´ì„œëŠ” ì´ ì •ë„ë¡œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìœ ëŸ½ ê°€ì´ë“œë¼ì¸ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, ë¨¼ì € TAVR ê°€ì´ë“œë¼ì¸ë¶€í„° ë§ì”€ë“œë¦´ê¹Œìš”? ìœ ëŸ½ ê°€ì´ë“œë¼ì¸ì— ëŒ€í•´ì„œëŠ” ì œê°€ FMR ê°€ì´ë“œë¼ì¸ì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <br><br>FMR ê´€ë ¨ ìœ ëŸ½ ê°€ì´ë“œë¼ì¸ì—ì„œëŠ” ì´ì œ ê¸°ëŠ¥ì„± ìŠ¹ëª¨íŒ ì—­ë¥˜ì¦(functional mitral regurgitation)ì´ ì‹¬ë¶€ì „ ì…ì› ê°ì†Œë¥¼ ìœ„í•´ Class I ê¶Œê³ ë“±ê¸‰ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. íŠ¹íˆ ìŠ¹ëª¨íŒê³¼ ì‚¼ì²¨íŒ ì§ˆí™˜ì— ëŒ€í•œ ì¸ì‹ì´ ë†’ì•„ì§€ê³  ìˆê³ , ì´ë²ˆ ê°€ì´ë“œë¼ì¸ ë³€ê²½ìœ¼ë¡œ í™˜ì ì˜ë¢°ê°€ ì¦ê°€í•˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ì§€ê¸ˆê¹Œì§€ ë³´ì•„ì˜¨ ë‘ ìë¦¿ìˆ˜ ì‹œì¥ ì„±ì¥ì„¸ë¥¼ ì§€ì†í•˜ëŠ” ë° ë„ì›€ì´ ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. <br><br>TAVR ê°€ì´ë“œë¼ì¸ì— ëŒ€í•œ ì½”ë©˜íŠ¸ëŠ” Danì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Joanne, as you may recall, the guidelines on the TAVR side changed in a meaningful way on two fronts. One is they reduce the age recommendation for TAVR going from 75% to 70%, right? That's one big element of the change. And then the other element was this whole concept of recommending proactive disease management regardless of symptom or heart function. So this is basically taking -- changing the dogma of watchful waiting in Europe. And so this is a huge shift. Now that is a -- that requires a lot of education. You can imagine, we're seeing -- definitely, we did see healthy procedural growth in Q4 in Europe and some of the large countries contributed to that in a meaningful way. But the way that we look at this is the guidelines won't be a light switch, whether it be in Europe or the U.S. or Japan, but give us an opportunity as those get disseminated as those get democratized and then put into practice, it's just layers and layers of durable growth for us. And so that's kind of how it's playing out, not a light switch, but definitely momentum.</td><td>**Daniel Lippis:** JAPAC(ì¼ë³¸, ëŒ€ì¤‘í™”ê¶Œ ë° ì•„ì‹œì•„íƒœí‰ì–‘) ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>ì¡°ì•¤, ê¸°ì–µí•˜ì‹œê² ì§€ë§Œ TAVR ìª½ ê°€ì´ë“œë¼ì¸ì´ ë‘ ê°€ì§€ ì¸¡ë©´ì—ì„œ ì˜ë¯¸ ìˆê²Œ ë³€ê²½ë˜ì—ˆìŠµë‹ˆë‹¤. ì²«ì§¸ëŠ” TAVR ê¶Œê³  ì—°ë ¹ì„ 75ì„¸ì—ì„œ 70ì„¸ë¡œ ë‚®ì¶˜ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ë³€ê²½ì‚¬í•­ì˜ í° ì¶• ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ë¥¸ í•˜ë‚˜ëŠ” ì¦ìƒì´ë‚˜ ì‹¬ì¥ ê¸°ëŠ¥ê³¼ ë¬´ê´€í•˜ê²Œ ì ê·¹ì ì¸ ì§ˆí™˜ ê´€ë¦¬ë¥¼ ê¶Œê³ í•œë‹¤ëŠ” ê°œë…ì…ë‹ˆë‹¤. ê¸°ë³¸ì ìœ¼ë¡œ ìœ ëŸ½ì—ì„œì˜ ê²½ê³¼ê´€ì°°(watchful waiting) ê´€í–‰ì„ ë°”ê¾¸ëŠ” ê²ƒì´ì£ . ì´ê±´ ì—„ì²­ë‚œ ë³€í™”ì…ë‹ˆë‹¤. ë¬¼ë¡  ì´ë¥¼ ìœ„í•´ì„œëŠ” ìƒë‹¹í•œ êµìœ¡ì´ í•„ìš”í•©ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ìš°ë¦¬ëŠ” 4ë¶„ê¸° ìœ ëŸ½ì—ì„œ í™•ì‹¤íˆ ê±´ì „í•œ ì‹œìˆ  ì„±ì¥ì„ ë³´ì•˜ê³ , ì¼ë¶€ ì£¼ìš” êµ­ê°€ë“¤ì´ ì˜ë¯¸ ìˆëŠ” ë°©ì‹ìœ¼ë¡œ ì´ì— ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ê°€ ë³´ëŠ” ê´€ì ì€ ê°€ì´ë“œë¼ì¸ì´ ìœ ëŸ½ì´ë“  ë¯¸êµ­ì´ë“  ì¼ë³¸ì´ë“  ìŠ¤ìœ„ì¹˜ë¥¼ ì¼œë“¯ ê°‘ìê¸° ì ìš©ë˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê°€ì´ë“œë¼ì¸ë“¤ì´ ë³´ê¸‰ë˜ê³  ëŒ€ì¤‘í™”ë˜ë©´ì„œ ì‹¤ì œë¡œ ì ìš©ë˜ëŠ” ê³¼ì •ì„ ê±°ì¹˜ê²Œ ë˜ëŠ”ë°, ì´ëŠ” ì €í¬ì—ê²Œ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì˜ ì—¬ëŸ¬ ì¸µìœ„ë¥¼ ìŒ“ì•„ê°€ëŠ” ê¸°íšŒê°€ ë©ë‹ˆë‹¤. ê·¸ë˜ì„œ í˜„ì¬ ìƒí™©ì´ ê·¸ë ‡ê²Œ ì „ê°œë˜ê³  ìˆìŠµë‹ˆë‹¤. ìŠ¤ìœ„ì¹˜ë¥¼ ì¼œë“¯ ì¦‰ê°ì ì¸ ë³€í™”ëŠ” ì•„ë‹ˆì§€ë§Œ, ë¶„ëª…í•œ ëª¨ë©˜í…€ì€ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from Matt Taylor with Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Jefferiesì˜ Matt Taylorë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Matthew Taylor: Jefferies LLC, Research Division I wanted to dig into the better performance we've seen in TAVR, especially in the U.S. the last couple of quarters and just ask you what you thought was causing that you're not benefiting from Boston. There really are you gaining share? Can you estimate how much EARLY TAVR has been contributing? Or are there other factors? What's really caused the increase in growth in the U.S. in the last couple of quarters?</td><td>**Matthew Taylor:** ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ íŠ¹íˆ ë¯¸êµ­ì—ì„œ TAVRì˜ ê°œì„ ëœ ì‹¤ì ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ê³¼ì˜ ì›ì¸ì´ ë¬´ì—‡ì´ë¼ê³  ìƒê°í•˜ì‹œëŠ”ì§€ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤. Bostonìœ¼ë¡œë¶€í„° í˜œíƒì„ ë°›ê³  ìˆëŠ” ê²ƒì€ ì•„ë‹ˆì–ì•„ìš”. ì‹¤ì œë¡œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ê³„ì‹  ê±´ê°€ìš”? EARLY TAVRì´ ì–¼ë§ˆë‚˜ ê¸°ì—¬í–ˆëŠ”ì§€ ì¶”ì •í•  ìˆ˜ ìˆìœ¼ì‹ ê°€ìš”? ì•„ë‹ˆë©´ ë‹¤ë¥¸ ìš”ì¸ë“¤ì´ ìˆë‚˜ìš”? ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ë¯¸êµ­ì—ì„œ ì„±ì¥ë¥ ì´ ì¦ê°€í•œ ì‹¤ì§ˆì ì¸ ì›ì¸ì´ ë¬´ì—‡ì¸ê°€ìš”?</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) So yes, thanks for the question. And I think without trying to be on repeat here, but this data, this very, very compelling data, not just on the early TAVR and the asymptomatic side and not just clinical but also economic data. I mean, I can't stress how important the economic data -- benefit of economic -- of the economics -- treatment of patients and the hospital economics earlier in the disease pathway is having an effect as much as the clinical data. So these two things tied with definitive durability data is creating a wave of confidence in the community to have a different conversation. It is also forcing, if you like, the aortic stenosis patient, the TAVR patient to be prioritized differently and to be treated with urgency. Typically, you might see a little bit more rearranging of the patient list to bring more sick patients to the front of the list and the more healthier patients towards the back of the list rather than just getting through the list. And this conversation is completely different now, and people are focusing on this intentional and urgent treatment of symptomatic AS. So this is regardless of whether the patient is asymptomatic or not. This is the impact that it is having on symptomatic aortic stenosis is what we see largely driving our growth. When we look at the claims data, we don't see asymptomatic patients coming in, in waves through the claims data. And that shouldn't be a surprise because the NCD doesn't cover asymptomatic indications at the moment. So right now, that's not a huge surprise. What we do see, though, since the indication in the United States, we do see increase in the number of echoes. We do see increase in the number of referrals. We do see a decrease in time from referral to CT, which is the heart team evaluation. And interestingly enough, we do see a relatively sharp increase in stress tests for patients and nobody typically likes to do stress tests. And so that's also an interesting finding that we see in the data. And so definitively, this is all positive momentum, and it's driving a lot of growth. But as I mentioned before, the other thing that is supporting and contributing to the performance in Q3 and Q4 is the success of SAPIEN 3 Ultra RESILIA. That's making a meaningful contribution to our performance, and we're pretty happy with that.</td><td>**Daniel Lippis:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ê°™ì€ ë§ì„ ë°˜ë³µí•˜ë ¤ëŠ” ê±´ ì•„ë‹ˆì§€ë§Œ, ì´ ë°ì´í„°ë“¤, ì •ë§ ì„¤ë“ë ¥ ìˆëŠ” ë°ì´í„°ë“¤ì´ ì¡°ê¸° TAVR(ê²½ì¹´í…Œí„° ëŒ€ë™ë§¥íŒë§‰ ì¹˜í™˜ìˆ )ê³¼ ë¬´ì¦ìƒ í™˜ì ì¸¡ë©´ì—ì„œë¿ë§Œ ì•„ë‹ˆë¼ ì„ìƒì  ì¸¡ë©´ë¿ ì•„ë‹ˆë¼ ê²½ì œì  ì¸¡ë©´ì—ì„œë„ ë‚˜ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ê²½ì œì  ë°ì´í„°ê°€ ì–¼ë§ˆë‚˜ ì¤‘ìš”í•œì§€ ì•„ë¬´ë¦¬ ê°•ì¡°í•´ë„ ì§€ë‚˜ì¹˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì§ˆë³‘ ê²½ë¡œ ì´ˆê¸°ì— í™˜ìë¥¼ ì¹˜ë£Œí•˜ëŠ” ê²ƒì˜ ê²½ì œì  íš¨ê³¼, ë³‘ì› ê²½ì œì„± ì¸¡ë©´ì—ì„œì˜ íš¨ê³¼ê°€ ì„ìƒ ë°ì´í„°ë§Œí¼ì´ë‚˜ í° ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë‘ ê°€ì§€ ìš”ì†Œê°€ í™•ì‹¤í•œ ë‚´êµ¬ì„± ë°ì´í„°ì™€ ê²°í•©ë˜ë©´ì„œ ì˜ë£Œê³„ì—ì„œ ì™„ì „íˆ ë‹¤ë¥¸ ì°¨ì›ì˜ ëŒ€í™”ë¥¼ ë‚˜ëˆŒ ìˆ˜ ìˆë‹¤ëŠ” ìì‹ ê°ì˜ ë¬¼ê²°ì„ ë§Œë“¤ì–´ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ëŒ€ë™ë§¥íŒë§‰í˜‘ì°©ì¦ í™˜ì, ì¦‰ TAVR í™˜ìë“¤ì˜ ìš°ì„ ìˆœìœ„ë¥¼ ë‹¤ë¥´ê²Œ ì„¤ì •í•˜ê³  ê¸´ê¸‰í•˜ê²Œ ì¹˜ë£Œí•˜ë„ë¡ ë§Œë“¤ê³  ìˆìŠµë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œëŠ” ë‹¨ìˆœíˆ ëŒ€ê¸°ì ëª…ë‹¨ì„ ìˆœì„œëŒ€ë¡œ ì²˜ë¦¬í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, ì¤‘ì¦ í™˜ìë“¤ì„ ì•ìœ¼ë¡œ ë°°ì¹˜í•˜ê³  ìƒëŒ€ì ìœ¼ë¡œ ê±´ê°•í•œ í™˜ìë“¤ì„ ë’¤ë¡œ ë¯¸ë£¨ëŠ” ë°©ì‹ìœ¼ë¡œ í™˜ì ëª…ë‹¨ì„ ì¬ì¡°ì •í•˜ëŠ” ëª¨ìŠµì„ ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ì œ ì´ëŸ¬í•œ ë…¼ì˜ëŠ” ì™„ì „íˆ ë‹¬ë¼ì¡Œê³ , ì‚¬ëŒë“¤ì€ ì¦ìƒì´ ìˆëŠ” ëŒ€ë™ë§¥íŒë§‰í˜‘ì°©ì¦ì— ëŒ€í•œ ì˜ë„ì ì´ê³  ê¸´ê¸‰í•œ ì¹˜ë£Œì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í™˜ìê°€ ë¬´ì¦ìƒì¸ì§€ ì—¬ë¶€ì™€ ê´€ê³„ì—†ì´ ì ìš©ë©ë‹ˆë‹¤. ì¦ìƒì´ ìˆëŠ” ëŒ€ë™ë§¥íŒë§‰í˜‘ì°©ì¦ì— ë¯¸ì¹˜ëŠ” ì´ëŸ¬í•œ ì˜í–¥ì´ ìš°ë¦¬ì˜ ì„±ì¥ì„ ì£¼ë„í•˜ëŠ” ì£¼ìš” ìš”ì¸ì…ë‹ˆë‹¤. ì²­êµ¬ ë°ì´í„°ë¥¼ ì‚´í´ë³´ë©´, ë¬´ì¦ìƒ í™˜ìë“¤ì´ ëŒ€ê·œëª¨ë¡œ ìœ ì…ë˜ëŠ” í˜„ìƒì€ ë³´ì´ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ NCDê°€ ë¬´ì¦ìƒ ì ì‘ì¦ì„ ë³´ì¥í•˜ì§€ ì•Šê¸° ë•Œë¬¸ì— ê·¸ë‹¤ì§€ ë†€ë¼ìš´ ì¼ì€ ì•„ë‹™ë‹ˆë‹¤. ë”°ë¼ì„œ í˜„ ì‹œì ì—ì„œëŠ” ì˜ˆìƒ ê°€ëŠ¥í•œ ê²°ê³¼ì…ë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ë¯¸êµ­ì—ì„œ ì ì‘ì¦ ìŠ¹ì¸ ì´í›„ ì‹¤ì œë¡œ í™•ì¸ë˜ëŠ” ê²ƒì€, ì‹¬ì´ˆìŒíŒŒ ê²€ì‚¬ ê±´ìˆ˜ê°€ ì¦ê°€í•˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì˜ë¢° ê±´ìˆ˜ë„ ì¦ê°€í•˜ê³  ìˆê³ ìš”. ì˜ë¢°ë¶€í„° CT ì´¬ì˜ê¹Œì§€, ì¦‰ ì‹¬ì¥íŒ€ í‰ê°€ê¹Œì§€ ì†Œìš”ë˜ëŠ” ì‹œê°„ì€ ê°ì†Œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í¥ë¯¸ë¡­ê²Œë„, í™˜ìë“¤ì˜ ë¶€í•˜ ê²€ì‚¬ê°€ ìƒë‹¹íˆ ê¸‰ê²©í•˜ê²Œ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ ë¶€í•˜ ê²€ì‚¬ë¥¼ ì„ í˜¸í•˜ëŠ” ì‚¬ëŒì€ ë§ì§€ ì•Šì€ë° ë§ì´ì£ . ì´ê²ƒë„ ë°ì´í„°ì—ì„œ ë°œê²¬í•œ ë§¤ìš° í¥ë¯¸ë¡œìš´ ì ì…ë‹ˆë‹¤. <br><br>ê²°ë¡ ì ìœ¼ë¡œ, ì´ ëª¨ë“  ê²ƒì´ ê¸ì •ì ì¸ ëª¨ë©˜í…€ì´ë©°, ìƒë‹¹í•œ ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, 3ë¶„ê¸°ì™€ 4ë¶„ê¸° ì‹¤ì ì„ ë’·ë°›ì¹¨í•˜ê³  ê¸°ì—¬í•˜ëŠ” ë˜ ë‹¤ë¥¸ ìš”ì¸ì€ SAPIEN 3 Ultra RESILIAì˜ ì„±ê³µì…ë‹ˆë‹¤. ì´ ì œí’ˆì´ ìš°ë¦¬ ì‹¤ì ì— ì˜ë¯¸ ìˆëŠ” ê¸°ì—¬ë¥¼ í•˜ê³  ìˆìœ¼ë©°, ì´ ë¶€ë¶„ì— ëŒ€í•´ ìƒë‹¹íˆ ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: And big picture here, if you process all of this that Dan talked about, this is what gives us confidence in our guidance for the year for TAVR, 6 to 8 and our guidance beyond 2026 for TAVR from mid- to high single digits. All what we are doing right now, all the things we have been doing, all of these catalysts are impacting severe symptomatic patients. And so the asymptomatic patients are still in front of us. This is why we are so confident as to have TAVR as the durable growth opportunity for Edwards.</td><td>**CEO & Director:** í° ê·¸ë¦¼ì—ì„œ ë³´ë©´, Danì´ ë§ì”€ë“œë¦° ëª¨ë“  ë‚´ìš©ì„ ì¢…í•©í•´ë³´ì‹œë©´, ì´ê²ƒì´ ë°”ë¡œ ì˜¬í•´ TAVR ì‚¬ì—…ì— ëŒ€í•œ 6~8% ê°€ì´ë˜ìŠ¤ì™€ 2026ë…„ ì´í›„ ì¤‘ê°„ì—ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ ìš°ë¦¬ì˜ í™•ì‹ ì„ ë’·ë°›ì¹¨í•˜ëŠ” ê·¼ê±°ì…ë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ê°€ í•˜ê³  ìˆëŠ” ëª¨ë“  ì¼ë“¤, ê·¸ë™ì•ˆ í•´ì˜¨ ëª¨ë“  ë…¸ë ¥ë“¤, ì´ ëª¨ë“  ì„±ì¥ ë™ë ¥ë“¤ì´ ì¤‘ì¦ ì¦ìƒ í™˜ìë“¤ì—ê²Œ ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬´ì¦ìƒ í™˜ìë“¤ì€ ì•„ì§ ìš°ë¦¬ ì•ì— ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ TAVRì„ Edwardsì˜ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ ê¸°íšŒë¡œ í™•ì‹ í•˜ëŠ” ì´ìœ ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from Vijay Kumar with Evercore ISI.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Evercore ISIì˜ Vijay Kumarë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division My first one was a quick housekeeping. Scott, I think you called out SAVR was impacted by some distributor adjustments. Could you quantify what that is? And is the Q1 guidance implying a 10% TAVR growth?</td><td>**Vijay Kumar:** ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ê°„ë‹¨í•œ í™•ì¸ ì‚¬í•­ì…ë‹ˆë‹¤. Scott, SAVRì´ ì¼ë¶€ ìœ í†µì—…ì²´ ì¡°ì •ì˜ ì˜í–¥ì„ ë°›ì•˜ë‹¤ê³  ë§ì”€í•˜ì‹  ê²ƒ ê°™ì€ë°ìš”. ê·¸ ê·œëª¨ë¥¼ êµ¬ì²´ì ìœ¼ë¡œ ì•Œë ¤ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  1ë¶„ê¸° ê°€ì´ë˜ìŠ¤ê°€ TAVR 10% ì„±ì¥ì„ ì˜ë¯¸í•˜ëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Scott Ullem: Corporate VP & CFO Sorry, Vijay, could you say the first part of your question one more time, please?</td><td>**Scott Ullem:** ì£„ì†¡í•©ë‹ˆë‹¤, Vijay, ì§ˆë¬¸ì˜ ì²« ë¶€ë¶„ì„ ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division Sorry. On SAVR, you called out a distributor impact in that Q4. Could you quantify what the impact is? Are those sales coming back in Q1? And just curious on what gets us to Q1 sales guidance? Is it SAVR? Are we modeling TAVR of 10% growth?</td><td>**Vijay Kumar:** <translation><br><br>ì£„ì†¡í•©ë‹ˆë‹¤. SAVR ê´€ë ¨í•´ì„œ 4ë¶„ê¸°ì— ìœ í†µì—…ì²´ ì˜í–¥ì„ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. ê·¸ ì˜í–¥ì„ ìˆ˜ì¹˜í™”í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ ë§¤ì¶œì´ 1ë¶„ê¸°ì— íšŒë³µë˜ë‚˜ìš”? ê·¸ë¦¬ê³  1ë¶„ê¸° ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ ë‹¬ì„± ìš”ì¸ì´ ê¶ê¸ˆí•©ë‹ˆë‹¤. SAVRì¸ê°€ìš”? TAVRì€ 10% ì„±ì¥ìœ¼ë¡œ ëª¨ë¸ë§í•˜ë©´ ë˜ë‚˜ìš”?<br><br></translation></td></tr>
<tr><td>Scott Ullem: Corporate VP & CFO Yes, sure. Thanks for the question. Yes, the surgical inventory adjustment was in one country, it was the end of the year, and it was really adjusting inventories in the distribution channel. In China, we go through distributors, and we work very carefully on managing inventory levels. And so this is just something that we did at the end of the year. We still expect mid-single-digit growth from Surgical in 2026 and beyond. So think of this as a onetime event.</td><td>**Scott Ullem:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ìˆ˜ìˆ  ë¶€ë¬¸ì˜ ì¬ê³  ì¡°ì •ì€ í•œ êµ­ê°€ì—ì„œ ë°œìƒí–ˆìœ¼ë©°, ì—°ë§ì— ì´ë£¨ì–´ì§„ ê²ƒìœ¼ë¡œ ìœ í†µ ì±„ë„ ë‚´ ì¬ê³ ë¥¼ ì¡°ì •í•œ ê²ƒì…ë‹ˆë‹¤. ì¤‘êµ­ì—ì„œëŠ” ìœ í†µì—…ì²´ë¥¼ í†µí•´ ì œí’ˆì„ ê³µê¸‰í•˜ê³  ìˆìœ¼ë©°, ì¬ê³  ìˆ˜ì¤€ ê´€ë¦¬ì— ë§¤ìš° ì‹ ì¤‘ì„ ê¸°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ì¡°ì •ì€ ì—°ë§ì— ì§„í–‰í•œ í†µìƒì ì¸ ì¡°ì¹˜ì˜€ìŠµë‹ˆë‹¤. <br><br>2026ë…„ê³¼ ê·¸ ì´í›„ì—ë„ ìˆ˜ìˆ  ë¶€ë¬¸ì—ì„œ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ (mid-single-digit growth)ì„ ì—¬ì „íˆ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë²ˆ ê±´ì€ ì¼íšŒì„± ì´ë²¤íŠ¸ë¡œ ë³´ì‹œë©´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division</td><td>**Vijay Kumar:** I notice that the content you've provided appears to be just a header or attribution line ("Evercore ISI Institutional Equities, Research Division") without any actual Q&A content to translate.<br><br>Could you please provide the actual earnings call Q&A dialogue that needs to be translated? I'm ready to translate the management responses once you share the complete content.</td></tr>
<tr><td>Scott Ullem: Corporate VP & CFO Yes. So Q1, the guidance implies -- I mentioned before, on a reported basis, about 300 basis points higher than the underlying growth guidance. We haven't broken out specific underlying growth guidance, but know that the growth in the first half of the year is higher than the growth in the second half of the year. And overall, we're increasingly confident about the 6% to 8% full year growth guidance for TAVR.</td><td>**Scott Ullem:** ë„¤, 1ë¶„ê¸° ê°€ì´ë˜ìŠ¤ëŠ” ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ë³´ê³  ê¸°ì¤€ìœ¼ë¡œ ê¸°ì € ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ë³´ë‹¤ ì•½ 300bp ë†’ì€ ìˆ˜ì¤€ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. êµ¬ì²´ì ì¸ ê¸°ì € ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ë¥¼ ë³„ë„ë¡œ ì œì‹œí•˜ì§€ëŠ” ì•Šì•˜ì§€ë§Œ, ìƒë°˜ê¸° ì„±ì¥ë¥ ì´ í•˜ë°˜ê¸° ì„±ì¥ë¥ ë³´ë‹¤ ë†’ë‹¤ëŠ” ì ì€ ì•Œì•„ë‘ì‹œê¸° ë°”ëë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ë°˜ì ìœ¼ë¡œ TAVRì˜ ì—°ê°„ 6~8% ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ í™•ì‹ ì´ ì ì  ë” ì»¤ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division That's helpful. And then maybe one on the moderate AS. What is, I guess, the right way to think about moderate AS. When these patients are untreated, right, do they look like low-risk TAVR patients? Is this asymptomatic TAVR patients? What's the right way to think about moderate AS? And what's the underlying mortality rate in untreated moderate AS patients?</td><td>**Vijay Kumar:** ë„ì›€ì´ ë˜ì…¨ë‹¤ë‹ˆ ì¢‹ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¤‘ë“±ë„ ëŒ€ë™ë§¥íŒë§‰ í˜‘ì°©ì¦(moderate AS)ì— ëŒ€í•´ í•œ ê°€ì§€ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¤‘ë“±ë„ ëŒ€ë™ë§¥íŒë§‰ í˜‘ì°©ì¦ì„ ì–´ë–»ê²Œ ì´í•´í•˜ëŠ” ê²ƒì´ ì ì ˆí• ê¹Œìš”? ì´ í™˜ìë“¤ì´ ì¹˜ë£Œë°›ì§€ ì•Šì„ ê²½ìš°, ì €ìœ„í—˜ TAVR í™˜ìë“¤ê³¼ ë¹„ìŠ·í•œ ì–‘ìƒì„ ë³´ì´ë‚˜ìš”? ì•„ë‹ˆë©´ ë¬´ì¦ìƒ TAVR í™˜ìë“¤ê³¼ ìœ ì‚¬í•œê°€ìš”? ì¤‘ë“±ë„ ëŒ€ë™ë§¥íŒë§‰ í˜‘ì°©ì¦ì„ ì–´ë–»ê²Œ ì´í•´í•´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  ì¹˜ë£Œë°›ì§€ ì•Šì€ ì¤‘ë“±ë„ ëŒ€ë™ë§¥íŒë§‰ í˜‘ì°©ì¦ í™˜ìë“¤ì˜ ê¸°ì € ì‚¬ë§ë¥ ì€ ì–´ëŠ ì •ë„ì¸ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Maybe let me start with Vijay. And first, when we when we decide to start a big pivotal study, randomized study, multiyear randomized studies like this one, it is because we believe we can show the benefit to patients. It is because we believe it is a big opportunity. It is because we believe in that case, SAPIEN 3 will have a big positive impact on these patients. So that's just to make sure that you feel our confidence and our belief behind progress and the moderate AS patient population. Having said that, we know the importance of highly scientific clinical studies. And as a company relying a lot on world-class evidence, we are trying not to talk a lot about before having seen the results. We know the importance of it. But -- so it is why some studies are more like post-market studies, marketing studies. So people have a freedom to talk about it. And here, we want to have a very high bar in terms of clinical evidence. So we have confidence, belief. It's a large patient population, and we are going to wait TCT to share more about it. Now Dan, do you have anything that you want to share in addition to what I said here?</td><td>**CEO & Director:** ë¨¼ì € Vijayì˜ ì§ˆë¬¸ë¶€í„° ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ê°€ ì´ëŸ° ëŒ€ê·œëª¨ í”¼ë²— ì—°êµ¬, ë¬´ì‘ìœ„ ì—°êµ¬, ìˆ˜ë…„ê°„ì˜ ë¬´ì‘ìœ„ ì—°êµ¬ë¥¼ ì‹œì‘í•˜ê¸°ë¡œ ê²°ì •í•  ë•ŒëŠ” í™˜ìë“¤ì—ê²Œ í˜œíƒì„ ë³´ì—¬ì¤„ ìˆ˜ ìˆë‹¤ê³  ë¯¿ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í° ê¸°íšŒë¼ê³  ë¯¿ê¸° ë•Œë¬¸ì´ê³ , ì´ ê²½ìš° SAPIEN 3ê°€ ì´ëŸ¬í•œ í™˜ìë“¤ì—ê²Œ í° ê¸ì •ì  ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì´ë¼ê³  ë¯¿ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ê°€ ì§„í–‰ ì¤‘ì¸ ì—°êµ¬ì™€ ì¤‘ë“±ë„ ëŒ€ë™ë§¥ í˜‘ì°©ì¦ í™˜ìêµ°ì— ëŒ€í•´ ê°–ê³  ìˆëŠ” í™•ì‹ ê³¼ ë¯¿ìŒì„ ëŠë¼ì…¨ìœ¼ë©´ í•©ë‹ˆë‹¤.<br><br>ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, ì €í¬ëŠ” ê³ ë„ë¡œ ê³¼í•™ì ì¸ ì„ìƒ ì—°êµ¬ì˜ ì¤‘ìš”ì„±ì„ ì˜ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì„¸ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ê·¼ê±°ì— ë§ì´ ì˜ì¡´í•˜ëŠ” íšŒì‚¬ë¡œì„œ, ê²°ê³¼ë¥¼ ë³´ê¸° ì „ì—ëŠ” ë§ì€ ì´ì•¼ê¸°ë¥¼ í•˜ì§€ ì•Šìœ¼ë ¤ê³  ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ì¤‘ìš”ì„±ì„ ì˜ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì¼ë¶€ ì—°êµ¬ë“¤ì€ ì‹œíŒ í›„ ì—°êµ¬ë‚˜ ë§ˆì¼€íŒ… ì—°êµ¬ì— ê°€ê¹Œìš´ ì„±ê²©ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ° ê²½ìš°ì—ëŠ” ì‚¬ëŒë“¤ì´ ììœ ë¡­ê²Œ ì´ì•¼ê¸°í•  ìˆ˜ ìˆì£ . í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” ì„ìƒ ì¦ê±° ì¸¡ë©´ì—ì„œ ë§¤ìš° ë†’ì€ ê¸°ì¤€ì„ ì„¤ì •í•˜ê³ ì í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” í™•ì‹ ê³¼ ë¯¿ìŒì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ìƒë‹¹íˆ í° í™˜ìêµ°ì´ê³ , TCTì—ì„œ ë” ìì„¸í•œ ë‚´ìš©ì„ ê³µìœ í•  ì˜ˆì •ì…ë‹ˆë‹¤. Dan, ì œê°€ ë§ì”€ë“œë¦° ê²ƒì— ì¶”ê°€ë¡œ í•˜ì‹¤ ë§ì”€ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>Daniel Lippis: Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Yes. The only additional color that I would say is as we learned a ton from now asymptomatic EARLY TAVR trial about how unpredictable the nature of the diseases and any -- and this whole idea of that it's a progressive, predictable disease has been thrown out the window even on EARLY TAVR. And we -- this is not an asymptomatic trial, right? PROGRESS is not a symptomatic moderate, right? So we're talking about a symptomatic patient population. And we don't know the results of the trial. We don't know what it looks like. What we do know is it enrolled very fast, right? And that's usually a bit of an indicator of things. And so we're excited to sort of just learn more about how this can inform this patient population and how transcatheter therapies may fit into this. But until we see the data, until we get past TCT, there's not a lot more to add.</td><td>**Daniel Lippis:** ë„¤, ì¶”ê°€ë¡œ ë§ì”€ë“œë¦¬ìë©´ ë¬´ì¦ìƒ EARLY TAVR ì‹œí—˜ì„ í†µí•´ ìš°ë¦¬ê°€ ë°°ìš´ ì¤‘ìš”í•œ ì ì€ ì§ˆë³‘ì˜ íŠ¹ì„±ì´ ì–¼ë§ˆë‚˜ ì˜ˆì¸¡ ë¶ˆê°€ëŠ¥í•œì§€ì— ëŒ€í•œ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ì ì§„ì ì´ê³  ì˜ˆì¸¡ ê°€ëŠ¥í•œ ì§ˆë³‘ì´ë¼ëŠ” ê¸°ì¡´ì˜ ê°œë…ì€ EARLY TAVR ì‹œí—˜ì—ì„œì¡°ì°¨ ì™„ì „íˆ ë’¤ì§‘ì–´ì¡ŒìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  PROGRESSëŠ” ë¬´ì¦ìƒ ì‹œí—˜ì´ ì•„ë‹™ë‹ˆë‹¤. PROGRESSëŠ” ì¦ìƒì´ ìˆëŠ” ì¤‘ë“±ë„ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ê°€ ë‹¤ë£¨ê³  ìˆëŠ” ê²ƒì€ ì¦ìƒì´ ìˆëŠ” í™˜ìêµ°ì…ë‹ˆë‹¤. <br><br>ì‹œí—˜ ê²°ê³¼ê°€ ì–´ë–»ê²Œ ë‚˜ì˜¬ì§€ëŠ” ì•„ì§ ëª¨ë¦…ë‹ˆë‹¤. ì–´ë–¤ ëª¨ìŠµì¼ì§€ë„ ëª¨ë¦…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ê°€ í™•ì‹¤íˆ ì•„ëŠ” ê²ƒì€ í™˜ì ë“±ë¡ì´ ë§¤ìš° ë¹ ë¥´ê²Œ ì§„í–‰ë˜ì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ê²ƒì€ ë³´í†µ ì–´ë–¤ ê²ƒë“¤ì„ ì‹œì‚¬í•˜ëŠ” ì§€í‘œê°€ ë˜ê³¤ í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì—°êµ¬ê°€ í•´ë‹¹ í™˜ìêµ°ì— ëŒ€í•´ ì–´ë–¤ ì •ë³´ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ê²½ì¹´í…Œí„° ì¹˜ë£Œë²•(transcatheter therapies)ì´ ì–´ë–»ê²Œ ì ìš©ë  ìˆ˜ ìˆëŠ”ì§€ ë” ì•Œì•„ê°€ëŠ” ê²ƒì— ëŒ€í•´ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹¤ì œ ë°ì´í„°ë¥¼ í™•ì¸í•˜ê¸° ì „ê¹Œì§€, TCTê°€ ëë‚˜ê¸° ì „ê¹Œì§€ëŠ” ë” ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ë‚´ìš©ì´ ë§ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. And ladies and gentlemen, we have reached the end of the question-and-answer session. So I will now hand the floor back over to Bernard Zovighian for closing remarks. Thank you.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ì§ˆì˜ì‘ë‹µ ì„¸ì…˜ì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì´ì œ ë§ˆë¬´ë¦¬ ë§ì”€ì„ ìœ„í•´ Bernard Zovighianì—ê²Œ ë‹¤ì‹œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. Thank you so much. Thanks for your continued interest in Edwards. Scott, Gerianne and myself, welcome any additional questions by telephone. Thank you so much, and have a great rest of your day.</td><td>**CEO & Director:** ê°ì‚¬í•©ë‹ˆë‹¤. Edwardsì— ëŒ€í•œ ì§€ì†ì ì¸ ê´€ì‹¬ì— ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. Scott, Gerianne, ê·¸ë¦¬ê³  ì €ëŠ” ì „í™”ë¡œ ì¶”ê°€ ì§ˆë¬¸ì„ í™˜ì˜í•©ë‹ˆë‹¤. ì •ë§ ê°ì‚¬ë“œë¦¬ë©°, ë‚¨ì€ í•˜ë£¨ ì¢‹ì€ ì‹œê°„ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. And this concludes today's conference. All parties may disconnect. Thank you.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ë¥¼ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ëª¨ë“  ì°¸ì„ìë¶„ë“¤ì€ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Edwards Lifesciences ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œ ìš”ì•½<br><br>## ì£¼ìš” ë‚´ìš©<br><br>â€¢ **TAVR ì‚¬ì—… ê°•ë ¥í•œ ì„±ì¥**: 4ë¶„ê¸° TAVR ë§¤ì¶œ 10.6% ì„±ì¥ ë‹¬ì„±. Boston Scientificì˜ ìœ ëŸ½ ì‹œì¥ ì² ìˆ˜ë¡œ ì¸í•œ ì‹œì¥ì ìœ ìœ¨ í™•ëŒ€ì™€ í•¨ê»˜ SAPIEN 3 Ultra RESILIAì˜ ê°•ë ¥í•œ ì±„íƒë¥ ì´ ì„±ì¥ ê²¬ì¸. 2026ë…„ TAVR ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ 6-8% ì œì‹œí•˜ë©°, ì¤‘ì¥ê¸°ì ìœ¼ë¡œ mid-to-high single digit ì„±ì¥ ì „ë§<br><br>â€¢ **4ë¶„ê¸° ê³µê²©ì  íˆ¬ì ë° ë§ˆì§„ ì „ë§**: 4ë¶„ê¸° SG&A ë¹„ìš©ì´ ì „ë…„ ëŒ€ë¹„ ì•½ 1ì–µ 1,200ë§Œ ë‹¬ëŸ¬ ì¦ê°€. í™˜ì ì ‘ê·¼ì„± ê°œì„ , ë¬´ì¦ìƒ í™˜ì ëŒ€ìƒ ë§ˆì¼€íŒ…, ìœ ëŸ½ ê°€ì´ë“œë¼ì¸ ë³€ê²½ ëŒ€ì‘ ë“±ì— ì§‘ì¤‘ íˆ¬ì. 2026ë…„ ì˜ì—…ì´ìµë¥ ì€ 28-29% ìƒë‹¨ ì˜ˆìƒ (JenaValve ì¸ìˆ˜ ì² íšŒë¡œ ë¹„ìš© ì ˆê° íš¨ê³¼)<br><br>â€¢ **ìœ ëŸ½ ê°€ì´ë“œë¼ì¸ ë³€ê²½ íš¨ê³¼**: ìœ ëŸ½ TAVR ê°€ì´ë“œë¼ì¸ì´ ê¶Œì¥ ì—°ë ¹ì„ 75ì„¸ì—ì„œ 70ì„¸ë¡œ í•˜í–¥ ì¡°ì •í•˜ê³ , ì¦ìƒ ì—¬ë¶€ì™€ ë¬´ê´€í•˜ê²Œ ì¡°ê¸° ì¹˜ë£Œë¥¼ ê¶Œì¥í•˜ëŠ” ë°©í–¥ìœ¼ë¡œ ë³€ê²½. ë‹¨ê¸°ì  ìŠ¤ìœ„ì¹˜ íš¨ê³¼ë³´ë‹¤ëŠ” ì¤‘ì¥ê¸°ì  ì§€ì† ì„±ì¥ ë™ë ¥ìœ¼ë¡œ ì‘ìš©í•  ì „ë§<br><br>â€¢ **ì¤‘ë“±ë„ ëŒ€ë™ë§¥ í˜‘ì°©ì¦(Moderate AS) ì—°êµ¬ ê²°ê³¼ ëŒ€ê¸°**: PROGRESS ì„ìƒì‹œí—˜</p>
    <hr style="margin:50px 0;">
    
</body></html>